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G e n e r a 1 
Introduction 
Congenital bowel disorders 
The focus of this thesis is on two congenital disorders in which the bowel is 
affected, namely Congenital Short Bowel Syndrome (CSBS) and megacystis­
microcolon-intestinal hypoperistalsis syndrome (MMIHS). A shortened small 
intestine and malrotation are the main features in Congenital Short Bowel 
Syndrome (Figure 1). In megacystis-microcolon-intestinal hypoperistalsis 
syndrome the main features are a giant bladder (Figure 2A), a microcolon 
(Figure 2B) and hypoperistalsis, while a shortened small intestine is also seen 
in some patients.1 More than 40 cases with CSBS2 and more than 200 cases 
with MMIHS1 have been published in the literature. Both syndromes have been 
described in siblings of both sexes and in consanguineous families, and were 
therefore thought to have an autosomal recessive pattern of inheritance. The 
genetic cause of both disorders was unknown. 
Congenital Short Bowel Syndrome 
History 
Congenital Short Bowel Syndrome (CSBS) was first described by Hamilton et al 
in 1969.3 They described a 6-year old girl who was diagnosed with a shortened 
small intestine at the age of 7 months. The diagnosis was made by laparotomy 
for continuing symptoms of chronic diarrhoea with unknown cause. The patient 
also had a malrotation of the gut with a left-sided cecum and appendix. She 
did not have any other abnormalities except for a minor irregularity of the fifth 
middle phalanx of the hand. Her parents were unrelated and gave birth to five 
girls of whom three were healthy. One sibling died at the age of 1 month, and 
a week prior to death, a short small intestine and malrotation were detected at 
laparotomy.3 After this first publication of CSBS, more than 40 additional case 
reports followed. 
Clinical presentation 
Patients usually present early in life with bile-stained vomiting and diarrhoea or 
failure to thrive. A shortened small intestine and malrotation (Figure 1) are often 
detected by ultrasound and confirmed by laparotomy. Other reported anomalies 
are an absent appendix,4·6 volvolus,7·8 shortened colon,H,9 hypertrophic pyloric 
stenosis,10·15 and a patent ductus arteriosus.11•13 
CSBS patients need total parenteral nutrition (TPN) to survive. Unfortunately, 
most patients die of the complications of TPN, which include sepsis and liver 
failure.16 
Histological findings 
In most CSBS patients there are no abnormal histological findings in biopsy tissue 
of the gut.3•6•11 However, on studying bowel tissue of CSBS patients, Tanner et al 
described the presence of too many neurons in the ganglia, absent or reduced 
number of intrinsic argyrophilic ganglion cells, and neuronal nuclei with clumped 
chromatin, which is characteristic for neuroblasts.14 In addition, Schalamon et 
al observed an abnormal bowel wall with signs of neuronal intestinal dysplasia 
in their CSBS patients.17 In one CSBS patient heterotopic gastric mucosa was 
found.18 Unfortunately, histology specimens were not obtained from all cases. 
Genetics 
Familial occurrence of CSBS, in which siblings of both sexes were affected, was 
described in around 60% of the cases and consanguinity was seen in around 
Figure 1. Congenital Short Bowel Syndrome is characterized by a congenital shortened small 
intestine and malrotation. 
(Illustration: Tom de Vries Lentsch) 
•• • 
25% of the cases. An autosomal recessive pattern of inheritance was therefore 
suggested.10·13 However, in a few cases the condition was more likely to be 
X-linked.11•15 
Our identification of CLMP as the affected gene in autosomal recessive 
CSBS is described in Chapter 2 of this thesis, and our finding of FLNA as the 
affected gene in X-linked CSBS is described in Chapter 4. 
Pathogenesis 
The aetiology of CSBS is unknown. The first hypothesis, proposed by Hamilton 
et al in 1969 concerns a problem in the intestinal development between the 
7th and 10th week of the pregnancy, the stage in which an umbilical hernia is 
present in the human embryo. They believed a problem in the accommodation 
of the intestine into this umbilical coelom, or the return of the intestine from 
the umbilical coelom into the abdominal cavity, might cause CSBS.2•1 9 Others 
suggested that intrauterine volvulus or intussuception, leading to ischemia and 
autoanastomosis, and autoamputation or intrauterine vascular events might 
result in a congenital short small intestine.6•12•1 9 These hypotheses are supported 
by the fact that volvulus has been described in a few patients7•8 and that mouse 
models for FLNA show vascular defects.20,21 
As abnormal peristalsis has been observed in some CSBS patients, 
Sansaricq et al hypothesised that CSBS patients may lack synthesis of 
neurotransmitters.11 However, abnormal peristalsis is not reported in all patients. 
In addition, Schalamon et al suggested that CSBS patients lack growth­
stimulating hormones like epidermal growth factor, insulin-like growth factor, 
and human growth hormone. However, they did not observe abnormal hormone 
levels in their patient.17 
Megacystis-microcolon-intestinal hypoperistalsis syndrome 
History 
Megacystis-microcolon-intestinal hypoperistalsis syndrome was first described 
by Berdon et al in 1976. They described five affected girls with abdominal 
distension due to a giant bladder, microcolon and intestinal obstruction due 
to absent or reduced intestinal peristalsis.22 Two of these girls were siblings. 
After this publication more than 200 patients with MMIHS were reported in the 
B 
Microcolon 
Figl.l'e 2. In Megacystis-Microcolon-lntestinal Hypoperistalsis Syndrome the main features are 
a giant bladder (A), a microcolon (B) and hypoperistalsis. (Illustration: Tom de Vries Lentsch) 
literature.23 
Clinical presentation 
MMIHS might be identified during pregnancy by the ultrasound finding of an enlarged 
bladder at as early as 16 weeks' gestation. Both poly- and oligohydramnion 
have been reported. After birth, patients with MMIHS present with abdominal 
distension, bile-stained vomiting and the absence of spontaneous voiding. Plain 
abdominal films are usually suggestive for MMIHS. A megacystis and microcolon 
are detected at exploratory laporatomy and these are always found in MMIHS 
patients. Other features less frequently described in MMIHS patients include 
malrotation, short-bowel syndrome, dilated proximal small bowel and stenosis 
of the small bowel.23.24 
Management of MMIHS patients is difficult. Many prokinetic drugs have 
been tried, but are unsuccessful.24 Many different surgical interventions have 
been reported, also without success.23.24 Only around 20% of the reported 
patients were alive at the time of publication. Most patients die due to sepsis, 
malnutrition and multiple organ failure. Patients need total parenteral nutrition 
and multivisceral transplantation to survive.23 
Histological findings 
For about half of the reported MMIHS patients, histological studies were 
included. In most of them, there were no abnormalities of the nerves plexuses.23 
Hypoganglionosis,25 aganglionosis,26 hyperganglionosis25•26 and dysganglionosis27 
General Introduction 17 
were reported in single case reports. Immature ganglion cells were seen in some 
cases.27 Other abnormal histological findings include decreased or increased 
nerve fibres,24 decreased vasoactive intestinal polypeptide and peptide histidine 
methionine fibres, and increased substance P and leucine-enkephalin f ibres.28 
Abnormalities of the smooth muscle cells have also been reported. An 
absence of or markedly reduced interstitial cells of Cajal, a-smooth muscle 
actin, and other contractile and cytoskeletal proteins and vacuolar degeneration 
of the smooth muscle cells were reported in some patients.29•30 
Genetics 
Nineteen familial cases of MMIHS, affecting siblings of both sexes, have been 
reported in the literature. The parents were consanguineous in four families, so 
that an autosomal recessive pattern of inheritance has been suggested. More 
than twice as many females as males have been reported, suggesting MMIHS 
has a female predominance.23•24 However, until now, no genetic cause of the 
disease has been identified. 
In Chapter 7 of this thesis a genetic approach for identifying the cause 
of MMIHS is discussed. 
Pathogenesis 
The aetiology of MMIHS is unknown, with the proposed hypotheses mainly based 
on histological findings. Neuropathic25•27•28 and myopathic29•30 changes of the 
bowel wall are suggested to be the underlying cause of the disease. In addition, 
Jona et al thought that MMIHS patients might have a problem in acetylcholine 
storage or production. This was based on the positive effect of bethanechol, a 
cholinergic agent, on the small bowel peristalsis in their patient.31 
Mouse models of MMIHS include knockouts of the subunits of the nicotinic 
acetylcholine receptor: The a3-/- and 132-/-,134-/- mice show similar features to 
MMIHS, primarily an enlarged bladder:32•33 In addition, intestinal hypoperistalsis 
was present in the 132-/-,134-/- mice. The intestinal length was also reduced 
in these mice, but as the mice were also smaller in size it was reduced 
proportionally.33 Since the lack of the a3 subunit was seen in MMIHS tissues, 
it has been suggested to be the cause of MMIHS.34 However, Lev-Lehman et 
al performed mutation analysis in the human CHRNB4 and CHRNA3 genes in 
13 MMIHS patients and their family members and did not identify any loss-of­
function mutations.35 
Aims and outline of this thesis 
The aims of the research presented in this thesis were to identify and characterize 
the genes underlying Congenital Short Bowel Syndrome and megacystis­
microcolon-intestinal hypoperistalsis syndrome. 
In Chapter 2 we describe the identification of homozygous and compound 
heterozygous mutations in CLMP in seven CSBS patients from five different 
families. lmmunostainings on human embryos and knockdown experiments in 
zebrafish were performed in an attempt to understand the role of CLMP in the 
development of the intestine. Transfection of both wild-type and mutant CLMP 
showed mislocalization of the mutant CLMP. 
In Chapter 3 the function of CLMP is further studied, making use of T84 
cell lines overexpressing both WT and mutant CLMP. Assays were performed to 
determine the role of CLMP in migration, proliferation, viability and transepithelial 
electrical resistance formation. Furthermore we performed aggregation assays 
in CHO cells to determine the role of CLMP in adhesion. 
In Chapter 4 we describe how male patients with mutations in FLNA can 
present with Congenital Short Bowel Syndrome. A two-base-pair deletion in the 
second exon of FLNA was found in one X-linked family and in one isolated male 
CSBS patient. As the mother of the isolated patient did not carry the deletion, 
we concluded that this mutation occurred de nova in this patient. 
A case report of a female patient who presented with persistent pulmonary 
hypertension and Congenital Short Bowel Syndrome is described in Chapter 5. 
This case illustrates how additional genes might be involved in Congenital Short 
Bowel Syndrome besides CLMP and FLNA. 
In Chapter 6 we give an overview of all the literature on CSBS and, on the 
basis of this, we make a recommendation for genetic counselling. The aetiology 
of CSBS remains obscure but we propose some possible disease mechanisms. 
A genetic approach for identifying the gene underlying MMIHS is discussed 
in Chapter 7. Both homozygosity mapping and exome sequencing were used in 
an attempt to find the affected gene in this disease. 
A general discussion and future perspectives are presented in Chapter 8. 
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Background & aims. 
Short-bowel syndrome usually results from surgical resection of the small 
intestine for diseases such as intestinal atresias, volvulus, and necrotizing 
enterocolitis. Patients with congenital short-bowel syndrome (CSBS) are born 
with a substantial shortening of the small intestine, to a mean length of 50 cm, 
compared with a normal length at birth of 190-280 cm. They also are born with 
intestinal malrotation. Because CSBS occurs in many consanguineous families, 
it is considered to be an autosomal-recessive disorder. We aimed to identify and 
characterize the genetic factor causing CSBS. 
Methods. We performed homozygosity mapping using 610K single-nucleotide 
polymorphism arrays to analyze the genomes of 5 patients with CSBS. After 
identifying a gene causing the disease, we determined its expression pattern in 
human embryos. We also overexpressed forms of the gene product that were 
and were not associated with CSBS in Chinese Hamster Ovary and T84 cells 
and generated a zebrafish model of the disease. 
Results. We identified loss-of-function mutations in Coxsackie- and adenovirus 
receptor-like membrane protein (CLMP) in CSBS patients. CLMP is a tight­
junction-associated protein that is expressed in the intestine of human embryos 
throughout development. Mutations in CLMP prevented its normal localization 
to the cell membrane. Knock-down experiments in zebrafish resulted in general 
developmental defects, including shortening of the intestine and the absence 
of goblet cells. Because goblet cells are characteristic for the midintestine in 
zebrafish, which resembles the small intestine in human beings, the zebrafish 
model mimics CSBS. 
Conclusions. Loss-of-function mutations in CLMP cause CSBS in human 
beings, likely by interfering with tight-junction formation, which disrupts intestinal 
development. Furthermore, we developed a zebrafish model of CSBS. 
• Loss-of-function 
Introduction 
Patients with Congenital Short-Bowel Syndrome (CSBS) are born with a 
shortened small intestine. The mean length of the small intestine in CSBS 
patients is approximately 50 cm, compared to a normal length at birth of 190-
280 cm.1·3 Patients with CSBS may develop severe malnutrition as a result of 
the hugely reduced absorptive surface of the small intestine. This is similar to 
acquired Short-Bowel Syndrome (SBS) that results from surgical resection of the 
small intestine for diseases such as intestinal atresias, volvulus and necrotizing 
enterocolitis. CSBS usually is diagnosed by barium-contrast radiographs and 
confirmed by exploratory laparotomy. Infants with SBS, whether congenital or 
acquired, need parenteral nutrition to survive, although parenteral nutrition itself 
causes life-threatening complications such as sepsis and liver failure, and a high 
rate of mortality early in life. However, some long-term survivors of CSBS have 
been reported.4•7 Because consanguinity frequently is seen in families in whom 
CSBS occurs, an autosomal-recessive pattern of inheritance is suspected. Until 
now, nothing was known about the genetic cause of this disease. 
Here, we report the identification and characterization of the Coxsackie­
and adenovirus receptor- like membrane protein (CLMP) as a gene underlying 
CSBS. 
Family Patient Ethnicity Consanguinity Sex Length small Addlllonal Mutations 
bowel al birth features 
(cm) 
1 1 -1 German unknown Female 30 c.230delA, (p.E77Glsx24), exon 3 
(rel 5) -American Heterozygous frameshift 
c.821 G>A, exon 6 
Heterozygous splice site mutation 
2 2-1 Italian + Male unknown c.371T>A, (pV124D), exon 3 
Homozygous missense mutation 
3 3-1 Turkish + Male 47 Intestinal Homozygous deletion (with presumed 
(rel 7) neuronal inversion) in intron 1 
dysplasia 
3-2 Turkish + Female unknown Intestinal Homozygous deletion (with presumed 
neuronal inversion) in intron 1 
dysplasia 
4 4-1 Dutch unknown Female 54 Homozygous deletion of 12483 bp (including 
(rel 4) exon 2) 
5 5-1 Canadian unknown Male 50 c.664C> T (p.R222X), exon 5 
(rel 6) Homozygous nonsense mutation 
5-2 Canadian unknown Female unknown c.664C> T (p.R222X), exon 5 
Homozygous nonsense mutation 
Table 1. Clinical and molecular data from all congenital short-bowel syndrome patients. 
Patients and Methods 
Research Subjects 
T he CSBS patients included in this study, aged 0-26 years, were either described 
previously in the literature or were known to physicians in the field4-7 patients were 
born with a shortened small intestine with a length of 30 to 54 cm (see Table 
1 ). Patients, of whom some were seen by an experienced clinical geneticist, did 
not show any other clinical features besides CSBS. All parents were reported as 
normal. Patients 2-1 , 3-1 and 3-2 were from consanguineous families. All patients 
were Caucasians, except for patients 3-1 and 3-2 who were of Turkish ancestry. 
The study protocol was approved by the institutional and national ethics review 
committees at the University Medical Centre Groningen (NL31 708.042 .10), and 
written informed consent was obtained. 
Homozygosity Mapping 
Genomic DNA of all participants was extracted from peripheral lymphocytes 
by standard methods. A genome-wide scan was performed on 5 patients of 
families 1 -4 using the lllumina 610,000 single-nucleotide polymorphism (SNP) 
array (lllumina, San Diego, CA) according to the manufacturer's instructions . 
. • 
Homozygosity mapping was performed by an automatic search for a minimum 
of 400 markers in a row (rv2-3 MB) that were homozygous in at least 3 of the 
4 families, and identical for patient 3-1 and 3-2 (Because they were from the 
same consanguineous family). 
Mutation Screening 
Analysis of the 7 exons of CLMP (NM_024769.2) and the flanking intronic regions 
was performed in all patients and their parents as well as in 77 Caucasian 
control individuals (154 control chromosomes). For primer sequences see 
Supplementary Table 1. Sequencing was performed (forward and reverse) with 
dye labelled primers (Big Dye Terminator v3.1 Sequencing Kit; Applied Biosystems, 
Foster City, CA) on an ABI 3730 automated sequencer (Applied Biosystems). 
In Silica Analysis of the Missense Mutation 
After analysis of the CLMP protein sequence (NP _079045.1) with the blastp 
algorithm (available: http://blast.ncbi.nlm.nih.gov/Blast.cgi), homologous 
sequences were obtained. The program M-Coffee was used to align them (http:// 
www.tcoffee.org).8 
The effect of the missense mutation was evaluated by the Russell method 
at European Molecular Biology Laboratory (available: http://www.russell.embl­
heidelberg.de/aas/),9 the polymorphism phenotyping algorithm (http://genetics. 
bwh.harvard.edu/pph/) and the Sort Intolerant From Tolerant algorithm (http://sift. 
jcvi.org/). 
Functional Analysis of the Splice Site Mutation 
To determine the effect of the splice site mutation found in patient 1-1, we 
performed an exon trapping assay. We first generated polymerase chain 
reaction (PCR) 2.1-TOPO plasmids (lnvitrogen, Carlsbad,CA), containing 
the sequences of the exon of interest (wild-type or mutant) and the flanking 
intronic sequences. The sequence of interest was PCR-amplif ied using either 
a control or the patient's genomic DNA as the DNA template. We used the 
primers GGCG-Ecor1, 5'-AAACCTGCAAATACTCATTC-3', and GACG-BamH1, 
5'-AAGTGTTTGTTGAGGATAAG-3'. The amplification was performed using 
Phusion High-fidelity DNA polymerase (Finnzymes, Helsinki, Finland). The PCR 
• 
products were inserted into the PCR 2.1 Topo constructs and thereafter digested 
with BamH1 and EcoR. T he inserts from control and mutant subsequently were 
cloned into the exon trapping vector pSPL3 (invitrogen). T he inserts were checked 
by direct sequencing. 
Human embryonic kidney (HEK) 293 cells were grown in Dulbecco's 
modified Eagle medium supplemented with 10% fetal calf serum and 1 %  
antibiotic solution (penicillin/streptomycin; lnvitrogen) at 3 7  ° C  in 5% CO2 • 
Human embryonic kidney 293 cells were plated in 6-well plates containing 
6 x 105 cells/well. After 24 hours the cells were transfected with 1 µ of the 
corresponding plasmid using polyethylenimine (Polyscience, Inc, Warrington, 
PA) according to the manufacturer's instructions. T ransfections of the vector 
containing the wild-type sequences or the empty pSPL3 vector were used as 
controls. After 48 hours cells were lysed and RNA was isolated according to 
manufacturer's instructions (Qiagen, Venlo, T he Netherlands). A total of 5µ of 
total RNA was used as a template to synthesize complementary DNA (cDNA) 
using the cDNA primer pd(N)6 (GE Healthcare, Hoevelaken, The Netherlands). 
PCR was performed using the primers (SD6) 5'-CT GAGT CACCT GGACAACC- 3' 
and (SA2) 5'-AT CT CAGT GGTAT T T GT GAGC-3' and the following amplification 
program: 5 minutes at 94 °C, 35 cycles for 1 minute at 94 °C, 1 minute at 60°C 
and 5 minutes at 72°C, and a final elongation time of 10 minutes at 72 °C. 
Five microliters of cDNA was used for the PCR in a total volume of 50 µL. PCR 
products were checked by gel electrophoresis and the exon trapping results 
were confirmed by direct sequencing. 
Expression of Wild-Type and Mutant CLMP in Chinese Hamster Ova,y Cells and 
T84 Cells 
A pCMV6-CLMP-green fluorescent protein ( GFP) vector was obtained from 
Origene (Rockville, MD). T he missense mutation was introduced in this vector by 
site-directed mutagenesis (Stratagene, Amstelveen, Santa Clara, CA) (for primer 
sequences see Supplementary Table 2). The wild-type (WT ) and mutant cDNA were 
amplified using the primers CCGCC-Nhel, 5'-AT GT CCCT CCT CCT T CT CC-3', 
and GGGCGC-Xhol ,  5'-T CAGACCGT T T GGAAGGCT CT G-3'. The amplification 
was performed using Pushion High-fidelity DNA polymerase (Finnzymes). T he 
PCR products were inserted into PCR 2.1 -TOPO plasmid (lnvitrogen). The PCR 
2.1 Topo constructs were digested by Nhel and Xhol restriction enzymes and 
the fragments were cloned into the vector pCMV-internal ribosomal re-entry site 
(IRES) coupled to eGFP (GFP l ike protein). The clones were checked by direct 
sequencing. 
Chinese hamster ovary (CHO-K1) and human intestinal epithelial T84 
cel ls were grown in commercially available alpha modif ication of eagle's medium 
(AMEM) medium and Dulbecco's modified Eagle medium/F-12, respectively, 
supplemented with 4.5 mg/L L-glutamine, 10% heat-inactivated fetal bovine 
serum, and 1 % antibiotic solution (penicill in-streptomycin; all lnvitrogen). The 
cells were maintained at 37 °C in a humidified atmosphere with 5% CO2_ 
WT or mutant pCMV-CLMP-IRES-EGFP was transfected in CHO-K1 
cells and T84 cells (1.5 x 105) with Lipofectamine 2000 Transfection Reagent 
( lnvitrogen) in a 1 :3 dilution, and transfection efficiencies were evaluated by 
measuring EGFP expression by flow cytometry. 
To observe the cell localization of CLMP, transfected CHO-K1 cells were 
stained by immunofluorescence. Cells were cultured on glass coverslips (Becton 
D ickinson Labware, Franklin Lakes, NJ), and fixed with 4% paraformaldehyde 
(20 minutes). After fixation, cells were treated with 50mmol/L NH4CI for 10 
minutes, washed with PBS, and permeablilized with 0.1% Triton X-100 (Sigma 
Aldrich, Zwijndrecht, The Netherlands) in PBS for 5 minutes at room temperature. 
Nonspecific binding was blocked by cell treatment with PBS containing 5% bovine 
serum albumin, for 30 minutes at room temperature. Cells then were stained 
with a rabbit anti-human CLMP antibody (anti-AP000926.6, Sigma HPA002385, 
Sigma Aldrich), for 1 hour at a 1:100 dilution. An Alexa 594-conjugated goat 
anti-rabbit antibody (lnvitrogen) then was used as the secondary antibody. 
After a wash with PBS, each sample was mounted with Vectashield (Vector 
labs, Peterborough, United Kingdom) and 4',6-diamidino-2-phenylindole-stained. 
The cell staining was observed using a Zeiss microscope (lmager Z1, Zeiss, 
Sliedrecht, The Netherlands) with apotome and images were taken using the 
Axi ovisi on software (Zeiss). 
Transfected T84 cells were fixed with 4% paraformaldehyde at 37 °C for 
30 minutes. Cells then were treated with 0.1 mol/L glycine for 10 minutes, washed 
with PBS, and permeabilized with 0.1% Triton X-100 in PBS at room temperature 
for 2 minutes. Nonspecific binding was blocked by incubating the cells with 
PBS containing 1 % bovine serum albumin and 0.05% Tween 20 (Sigma Aldrich) 
at room temperature for 1 minute. Cells were immunolabeled with the rabbit 
polyclonal antibody for CLMP (anti-AP000926.6, Sigma HPA002385), in 1:100 
dilution at 37°C for 1 hour. Cells were subsequently washed 5 times with PBS and 
incubated with mouse monoclonal anti-zonula occludens 1 (ZO-1) antibodies 
(Zymed, San Francisco, CA) at 1:100 dilution. An Alexa-546-conjugated goat 
anti-rabbit antibody (lnvitrogen) and a Cy5-conjugated goat anti-mouse antibody 
were used as secondary antibodies both at a 1:500 dilution. 4',6-diamidino-2-
phenylindole (at a 1:1000 dilution) and/or DRAQ5 (Cell Signaling Technology, 
Leiden, The Netherlands) (at a 1 :500 dilution) were used for nuclear staining. 
After a wash with PBS, samples were mounted and analysed with a Leica SP2 
AOBS confocal laser scanning microscope (Wetzlar, Germany). 
CLMP Expression During Human Development 
CLMP expression was examined by immunohistochemistry in human embryos 
and fetal tissue obtained from terminated pregnancies using the mifepristone 
protocol in concordance with French legislation (94-654 and 08-400) and 
approved by the Necker Hospital Ethics Committee. Embryonic and fetal tissues 
were fixed in 4% paraformaldehyde, pH 7.4 or in 1 1% formaldehyde, 60% ethanol, 
and 10% acetic acid, embedded in paraffin blocks and sectioned at 5 mm. 
Sections were deparaffinized, rinsed in PBS and incubated 30 minutes in 0.5 
mol/L ammonium chloride, rinsed again, and nonspecific binding was blocked 
by 10% fetal calf serum in PBS for 30 minutes. Classical antigen unmasking in 
citrate buffer was performed for 20 minutes. Slides were incubated overnight 
at 4 °C in a humid chamber with the rabbit primary anti-human CLMP antibody 
(anti-AP000926.6, Sigma HPA002385) at a 1:50 di lution in PBS with 2% fetal 
calf serum and then rinsed. A goat anti-rabbit-alkaline phosphatase-conjugated 
secondary antibody was applied at 1 :200 dilution in PBS/2% fetal calf serum, 
and alkaline phosphatase activity was revealed by the standard nitro-blue­
tetrazolium chloride (NBT)-5- bromo-4-chloro-3'-indolyphosphat-p-toluidine 
salt (BCIP) chromogenic reaction to reveal the immunolocalization of CLMP. 
Adjacent sections stained without the primary antibody anti-human CLMP were 
used as negative controls. 
Expression Pattern of Orthologs in Zebrafish and Knock-Down Experiments 
Zebrafish were kept and bred under standard conditions at 28.5°C.1 0  Embryos 
were staged and fixed at specific hours after fertilization (hpf). Embryos were 
grown in media supplemented with 0.2 mmol/L 1-phenyl-2-thiourea (Sigma) to 
inhibit pigment formation.10 
A search for the predicted zebrafish orthologs of CLMP was performed 
in the Ensembl database (available: www.ensembl.org). To clone the complete 
open reading frames of the zebrafish orthologs, multiple reverse-transcription 
(RT)-PCR primers were designed to amplify 5' and 3' overlapping segments 
of the open reading frame based on the predicted sequences. The cDNA 
segments were subcloned and sequenced. Sequencher DNA sequence analysis 
software (Applied Biosystems) was used to assemble the resulting sequences. 
Rapid amplification of cDNA ends was used to amplify the 5' and 3' ends of 
the open reading frame. Rapid amplication of cDNA ends was isolated from 
72-hpf embryos using a Smart rapid amplification cDNA ends Amp I if ication Kit 
(Clonetech, Mountain View, CA). The resulting PCR products were subcloned 
and sequenced to complete the open reading frame sequence for the orthologs. 
The continuity of the full-length sequence was confirmed by RT-PCR on single­
stranded cDNA isolated from 48-hpf embryos. The orthologs were cloned and 
the sequences were determined by direct sequencing. 
Homology studies were completed using publicly accessible programs 
from SDSC Biology Workbench (San Diego, CA). ClustalW (SDSC) was used to 
align the amino acid sequences of both zebrafish orthologs (called CLMPa and 
CLMPb), rat, and human CLMP (called h.CLMP) (Supplementary Figure 2). 
To determine the temporal expression of CLMPa and CLMPb, RT-PCR was 
performed at various time points during embryonic and larval development. 
The primers used amplified a segment of the open reading frame spanning 
nucleotides 38-881 of CLMPa and nucleotides -3-851 of CLMPb. The following 
primers were used: CLMPa forward, 5'-GTGATGTCTGCCAGCGCTCG-3', 
CLMPa reverse, 5'- GGGACGACGACAGAGAGTTC-3', CLMPb 
forward, 5'- CTGCAGCTGACTGACTCTGG-3' and CLMPb reverse, 5'­
GTCTGAAAGGCCTTGCTTTG-3'. The predicted fragment sizes were as follows: 
for CLMPa, 843 base pairs and for CLMPb, 854 base pairs. To determine the 
spatial expression patterns of CLMPa and CLMPb, antisense digoxigenin-labeled 
probes for both genes were generated and whole mount in situ hybridization was 
performed as described by Thisse et a/.11 
Two different, nonoverlapping, translation-blocking morpholinos (TBMO), 
a splice-blocking morpholino (SBMO) and a 5-mispair morpholino were designed 
to target CLMPa and were generated by gene tools (www.gene-tools.com; for 
morpholino sequences see Supplementary Table 3). Morpholinos wered injected to 
determine the effects of knocking down CLMPa protein levels.12 The morpholinos 
were diluted in sterile filtered water over a range of concentrations from 1 to 10 
mg/ml. Approximately 1 nl of diluted morpholino was injected at the 1- to 2-cell 
stage using a gas-driven microinjection apparatus. The morpholino dilutions that 
resulted in a consistent knockdown of CLMPa were as follows: CLMPa TBMO1 
and TBMO2: 2mg/ml, SBMO: 1 mg/ml. A p53 translation-blocking morpholino 
was co-injected at a concentration of 1.5 times the morpholino concentration to 
rule out the possibility that the morphant phenotype was caused by a cytotoxic 
side effect of the morpholinos. A negative control 5-base pair mismatch 
morpholino based on the sequence of TBMO1 was generated and injected at a 
concentration of 2mg/ml (Supplementary Table 3). To verify the effectiveness of 
the CLMP SBMO, RT-PCR was performed on messenger RNA (mRNA) isolated 
from SBMO-injected and control embryos. The primers used for the RT-PCR 
were as follows: CLMPaRTPCR forward, 5'- CGCCCTGCTCTTAGTATTGC -3' 
and CLMP-aRTPCR reverse, 5'- GGGGTTTTGATGGCTTCAAG - 3'. 
H&E staining was performed on 3-mm paraffin sections from 96 hpf 
control and SBMO-injected embryos using standard procedures. The sections 
were heated for 20 minutes at 60°C, deparaffinised, and hydrated to water. 
The sections were stained in Haematoxylin 721 1  (Richard Allan Scientific, 
Kalamazoo, Ml) for 4 minutes, rinsed in water, immersed in Clarifier (Richard Allan) 
for 1 minute, and rinsed again in water. Subsequently, slides were immersed in 
Bluing (Richard Allan) for 1 minute, followed by a brief immersion in 95% ethanol, 
followed by a 45-seconds immersion in Eosin-Y 711 1  (Richard Allan). Slides then 
were dehydrated in 95% ethanol, followed by absolute ethanol, cleared in xylene, 
and coverslipped. 
For the rescue experiment CLMPa mRNA was made from a pCS2+ 
expression vector containing the complete Open Reading Frame sequence 
of the CLMPa ortholog. Synthetic mRNA was synthesized using a mMessage 
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mMachine kit (Life Technology, Bleiswijk ,  the Netherlands). 
Results 
Loss-of-Function Mutations in CLMP cause Congenital Short-Bowe/ Syndrome 
To map the disease gene we performed lllumina 610,000-SNP arrays on 5 patients 
(1-1 , 2-1, 3-1, 3-2 and 4-1; Figure 1A). We identified a homozygous region shared 
by 4 (patients 2-1, 3-1, 3-2 and 4-1) on 11  q24.1 ,  comprising approximately 
2 MB and containing 20 genes. In addition, a homozygous deletion in patient 
4-1 was identified that involved 5 SNPs (rs7113273, rs7109445, rs4936775, 
rs7121089 and rs11218981). This deletion leads to a loss of exonic and flanking 
intronic sequences of exon 2 of CLMP (also called adipocyte specific adhesion 
molecule [ASAM]). The deletion results in a frameshift and a premature stop 
codon. Through PCR and direct sequencing we confirmed that 12,483 base pairs 
were deleted. Direct sequencing of CLMP in the other patients revealed more 
mutations. Patient 1-1 was compound heterozygous, carrying a paternally derived 
heterozygous frameshift mutation (c.589delA) in exon 3, leading to a premature 
stop codon, and a maternally derived heterozygous potential splice donor site 
mutation (c.1180G>A). With an in vitro exon trapping assay, we confirmed that 
c.1 180G>A impairs splicing and likely excludes exon 6 (Supplementary Figure 
2A). For the WT sequences the exon was trapped, however, for the mutant 
it was not. Patient 2-1 carried a homozygous missense mutation (c.730T>A, 
p.V124D) in exon 3. This missense mutation of a highly conserved amino acid 
was predicted to be pathogenic by the Russell, polymorphism phenotyping, and 
Sort Intolerant From Tolerant programs (Supplementary Figure 28). In patients 
3-1 and 3-2 we did not find any mutations in the coding sequences of CLMP. 
We did identify a homozygous deletion (on the array) in the first intron of CLMP 
encompassing SNP rs7115102. We confirmed the presence of this deletion 
with PCR and we showed that this deletion co-segregates with the disease 
phenotype in this family (Supplementary Figure 2C). However, we were not able 
to fine-map the deletion using primers in the flanking region. PCR using primer 
sets flanking the deletion yielded the expected PCR product from controls (of 
around 5 kb), but no PCR product was detected in the patients (Supplementary 
Figure 1 C) , whereas a PCR product of around 4 kb was expected. As a result we 
hypothesized that an inversion might be present as a way to explain the fact that 
we were not able to amplify the flanking regions. However, using fluorescence 
in situ hybridization we were not able to identify a large inversion (data not 
shown), although a small inversion cannot be excluded. Finally, in patient 5-1, 
we found a homozygous nonsense mutation (c.664C> T, p.R222X) in exon 5. The 
mutations identified were not reported in any of the known SNP databases and 
all presumably are loss-of-function mutations (Table 1 and Figure 1 B), and all 
were inherited from nonaffected heterozygous parents (data not shown). None 
of the mutations were found in 154 control chromosomes of Caucasian origin. 
CLMP Expression During Human Development 
Because CSBS is a developmental anomaly of the intestine we determined the 
pattern of CLMP expression in the intestine during human embryonic development. 
lmmunostainings on human embryos at 7 and 8 weeks of development (Figure 2A 
and B) showed that CLMP was highly abundant in the rapidly dividing cells of the 
central and peripheral nervous systems, the mesenchyme of the frontonasal and 
mandibular processes, and the dermamyotome, and critically it was expressed 
in the endodermal derivatives of the foregut, midgut and hindgut, and also in 
the liver, lung, esophagus, and trachea. It was expressed less strongly in the 
prevertebral condensations and extra-embryonic tissues, and the dorsal head 
mesenchyme. During midterm fetal stages, 18 and 23 weeks of development 
(Figure 2C and E), increased immunoreactivity for CLMP was observed in the 
intestinal crypts while expression continued to be present in all tissues, with the 
lowest expression in the muscular and interstitial layers. Midterm liver and kidney 
tissues strongly express CLMP in the parenchyma of the lobules and cortex, 
respectively (Figure 2D and F). CLMP also was observed in the collecting ducts 
and to a lesser extent in the bile ducts and ureter. 
CLMP expression thus was seen in the intestine during different stages of 
human development. Because CLMP also was expressed in many other tissues, 
this argues for functional redundancy with a specific function of CLMP during 
intestinal development. 
Mutation of CLMP Abrogated its Normal Localization at the Cell Membrane 
CLMP encodes for a transmembrane protein belonging to the CTX (cortical 
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Figure 1. Identification of loss-of-function mutations in CLMP in congenital short-bowel 
syndrome patients. (A) An overlapping homozygous region (yellow bars) was found in 4 of 
the 5 patients on the array. A homozygous deletion (red bars) concerning exon 2 of CLMP 
was detected in patient 4-1 . (B) An overview of CLMP with its 7 exons and all the identified 
mutations. 
Loss-of-function mutations in CLMP cause autosomal recessive CSBS 37 
thymocyte marker) subfamily of the lmmunoglobulin superfamily. It acts as an 
adhesion molecule and co-localizes with tight junction proteins.13 To determine 
whether the missense mutation (c.730T>A, p.V124D) affected the normal cell 
membrane localization, we transfected CHO and T84 cells with pCMV-CLMP­
IRES-EGFP constructs. We expressed both the wild-type protein (CLMP-WT) and 
the mutant protein (c.730T>A, p.V124D, CLMP-mutant). CLMP was localized at 
the cell membrane when 2 neighboring CHO cells expressed the WT protein 
(Figure 3A). In contrast, the mutant protein was localized in the cytoplasm 
(Figure 3B). Similar results were obtained in a human intestinal epithelial cell 
model (T84 cells) (Figure 3C and D). However, expression of the WT protein in 
a cell that did not have a transfected neighboring cell resulted in the retention 
of the protein in intracellular punctate structures (Figure 3E). Because CLMP 
has been shown to co-localize with tight junction markers, we determined co­
localization of CLMP with the tight junction marker ZO-1. Importantly, WT protein 
showed co-localization with ZO-1, whereas the mutant protein did not (Figure 
4B, C, F and E, arrows). Again, CLMP was localized only to points of membrane 
apposition when 2 neighboring cells were both transfected. Overexpression of 
the WT protein did not alter the localization of ZO-1 (compare Figure 4D with E). 
Instead, expression of the mutant protein resulted in an increased cytoplasmic 
pool of ZO-1 (Figure 4F). 
Together, these results indicate that CLMP plays a role in tight junctions 
and that the mislocalization of the mutant protein influences the localization of 
the tight junction protein ZO-1. 
A Zebrafish Model for Congenital Short-Bowel Syndrome 
To understand the in vivo function of CLMP in intestinal development and gut 
length determination we investigated the function of CLMP orthologs in the 
zebrafish model organism. Analysis of the zebrafish genome (Sanger Zv8) 
revealed two potential zebrafish CLMP orthologs (ENSDARG00000003145 and 
ENSDARG00000073678) (Supplementary Figure 2). The temporal and spatial 
expression patterns of both orthologs were determined by in situ hybridizaton 
(Figure 5A). One ortholog ( CLMPa) specifically was expressed in the intestine at 
48 and 72 hours after fertilization, while the other ortholog ( CLMPb) had a much 





� 2. lmmunohistochemistry of CLMP on human embryo and fetal tissues shows expression of CLMP 
in the intestine and in many other tissues. (A) Carnegie stage 15 (circa 33-36 days post-fertilization), cross­
section, dorsal to left (and right, for tail bud). CLMP protein was expressed strongly by all embryonic tissues 
and the umbilical cord. Panel .A:-F': adjacent sections to panels A, B and D-F, nonspecific immunoglobulin­
negative controls. (B) Carnegie stage 18 (circa 44 days post-fertilization), parasagittal section, dorsal to 
right CLMP protein was abundant throughout the central and peripheral nervous systems, through the 
endodermal layer derivatives of the foregut, midgut and hindgut including the liver, lung, esophagus and 
trachea, and in the mesenchyme of the frontonasal and mandibular processes. (C and E) Cross- and 
tangential sections, respectively, of the small intestine and a portion of the large intestine at 18  weeks 
of development, with increased immunoreactivity in the crypts. (D) Liver parenchyme at 21 weeks of 
development strongly expressed CLMP, which also was present but to a lesser degree in the bile ducts. 
(F) Cross-section of kidney at 23 weeks of development, showing medullocortical expression gradient 
with more CLMP in the glomeruli than the collecting ducts, and only light expression in the ureteral smooth 
muscle. ao, aorta; bd, bile duct; drg, dorsal root ganglion; fn, frontonasal process; h, heart; int, midgut 
intestinal herniation (arrowheads in panel B); lu, lung; Iv, liver; md, mandible; nt, neural tube; oe, esophagus; 
rh, rhombencephalon; sc, spinal cord; st, stomach; tb, tailbud; tel, telencephalon; tr, trachea; ua, umbilical 
arteries; ur, ureter Scale bar. 1 mm. 
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whether loss-of-function of CLMPa leads to a CSBS-like phenotype in zebrafish, 
we performed a series of morpholino antisense knock-down experiments. 
Injection of either a T BMO or an SBMO morpholino targeting CLMPa resulted 
in a similar phenotype. Both SBMO and T BMO morphants showed a significant 
developmental delay. Morphants were smaller in overall body length as 
compared to WT controls. Likewise the length of the intestine was shorter in 








Figure 3. CLMP-mutant (c.730T >A, p.V124D) abrogated the normal cell membrane localization of 
CLMP when transiently expressed in CHO and human intestinal epithelial T 84 cells. (A) CLMP-WT 
localized to the cell-cell contact area of CHO cells. (B) In contrast, CLMP-mutant did not localize 
at the cell membrane but in the cytoplasm. (C) CLMP-WT localized at the cell membrane of human 
intestinal epithelial T 84 cells, (D) whereas CLMP-mutant did not. (E) Expression of CLMP-WT in a 
cell that did not have a CLMP-expressing neighbor cell caused an intracellular retention of CLMP in 
punctate structures. (F) CLMP-mutant did not show these structures. 
mm and 1.9 mm for WT vs morphant, respectively; P;;;;7.0637E-06, n=10 vs 9), 
however, this shortening was proportional to the overall shorter body length of 
the morphants (mean gut length, 15.36 and 15.5 somites for WT vs morphant, 
respectively, P;;;;Q.3211 ,  n;;;:11  vs 8). To confirm the specificity of the morpholino 
we generated an additional translation-blocking morpholino for CLMPa (TBMO2) 
(Supplementary Table 3), which caused a similar phenotype to that observed 
for the original CLMPa TBMO1 and SBMO (data not shown). A 5-base mis­
match control morpholino for TBMO1 was also generated and injected and 
this did not show any phenotype (data not shown). The potential nonspecific 
cytotoxic side effect of the morpholinos was excluded by co-injection of a p53 
translation-blocking morpholino (Supplementary Table 3). Critically, the knock­
down phenotype was rescued by co-injection of CLMPa mRNA with the SBMO 
(Figure 5B). 
H &E staining of sections of both 96 hpf control embryos and SBMO­
injected embryos showed a significant difference in the overall gut m orphology 
(Figure 5C). Goblet cells, which are characteristic of the midintestine in zebrafish, 
were seen in the control embryos but these cells were absent in the SBMO­
injected embryos (Figure 5C, arrowheads). The zebrafish midintestine resembles 
the small intestine in human beings.14 This result taken with the overall reduction 
in intestinal length observed in the morphants suggests that loss of function of 
CLMPa in zebrafish results in abnormal intestinal development that has some 
similarities to the CSBS clinical phenotype. 
Discussion 
Congenital short-bowel syndrome is a gastrointestinal disorder of which the 
genetic basis is unknown. Here we report the identification of a number of loss­
of-function mutations in the CLMP gene in patients with CSBS. The mutations 
we found are thought to result in a loss of CLMP function owing to nonsense 
mutations (family 5), frameshift/splicing mutations (family 1 and 4) and in 
mislocalization of the CLMP protein caused by a missense mutation (family 2). 
In addition, this missense mutation has an influence on the localization of the 
tight junction protein ZO-1. 
• • 
To understand how loss of function of CLMP leads to CSBS, we undertook 
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Flgll'e 4. CLMP-WT co-localizes with ZO-1 and CLMP-mutant (c.730T>A, p.V124D) resulted in an 
increase of cytoplasmic ZO-1 when transiently expressed in human intestinal epithelial T84 cells. 
(A) T84 cells do not express CLMP endogenously. (B) CLMP-WT co-localized with the tight junction­
associated protein ZO-1 (compare to E, affows). (C) CLMP-mutant failed to co-localize with the tight 
junction-associated protein ZO-1.  (D) Endogenous expression of ZO-1 in T84 cells. (E) Expression of 
CLMP-WT did not visibly alter the localization of ZO-1 (compare to D) (F) The intracellular expression 
of CLMP-mutant resulted in an increased cytoplasmic pool of ZO-1 that overlapped with CLMP­
mutant, but did not inhibit the localization of ZO-1 at the cell membrane (affows). 
a series of zebra fish experiments. We showed that a zebra fish ortholog ( CLMPa) 
is expressed in the intestine at 48 and 72 hpf. Knock-down of CLMPa in zebrafish 
resulted in a very severe phenotype including an affected intestine. A significant 
reduction in intestinal length was observed in the CLMPa morphants. Furthermore, 
CLMPa morphants also lacked goblets cells in the midintestine, suggesting that 
the CLMP function is required for normal small intestin development both in fish 
and human beings, and suggesting a potential evolutionary conservation in this 
gene's function. 
Given the wide expression of CLMP during both human and zebrafish 
development (as shown in Figures 2 and 5A) and the severe phenotype observed 
in the zebrafish CLMPa morphants, it is intriguing that the phenotype in the 

















CLMPa SBMO rescue 
CLMPa SBMO 
96hpf 
Fi'11'e 5. CLMPa ortholog is expressed in the intestine of zebrafish embryos and knock-down of 
this ortholog results in a shortened and maldeveloped intestine. (A) 24 hpf (1,11), 48 hpf (Ill, IV), and 
72 hpf N, VI) whole mount in situ hybridized zebrafish embryos hybridized with either CLMPa (I, Ill, V) 
or CLMPb (11,IV,VI) antisense riboprobes. Arrowheads (I, Ill, IV, V, VI) indicate intestinal expression of 
CLMP orthologs. (B) Effect of CLMPa SBMO on morphological development. Lateral views of control 
{I, IV, VII) CLMPa SBMO alone (II, V, VIII) and CLMPa SBMO plus CLMPa mRNA-(1 1 1 ,  VI, IX) injected 
embryos at 48 hpf {I, 1 1 ,  Ill), 72 hpf (IV, V, VI) and 96 hpf Ml, VIII, IX). (C) H&E stained parasagittal 
cross-sections of 96 hpf control {I, Ill and V) and CLMPa morphant (II, IV, VI) embryos. Arrowheads 
(V) indicate goblet cells. Intestinal muscle layer (m) and intestinal epithelia (e) are indicated {V, VI). (D) 
Knock-down of CLMPa verified by RT-PCR. Splice-blocking morpholino-injected embryos (S) show 
abnormal RT-PCR products as compared to the WT embryos (C). (E) The length of the intestine of 
the SBMO-injected embryos was significantly shorter. All scale bars : 50µ. 
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study do not have additional clinical features besides malrotation and intestinal 
neuronal dysplasia, which was reported only in patients 3-1 and 3-2. T his all 
argues for functional redundancy of CLMP in human beings. 
We have shown that loss-of-function mutations of CLMP underlie CSBS, 
and we can further speculate on the pathogenesis of this disease. We and 
others have shown that CLMP co-localizes with tight junction proteins. It is 
known that overexpression of CLMP in CHO cells induces cell aggregation and 
overexpression of CLMP in Madin- Darby canine kidney cells enhances trans­
epithelial resistance.13 Thus CLMP might play a crucial role in tight junction 
formation and functions. Because tight junction markers such as ZO-1 and its 
interacting protein zonula occludens 1 (ZO-1)- associated nuclei acid binding 
protein play an important role in cell proliferation,15·16 loss of function of CLMP 
also may play a crucial role in downregulation of proliferation of the small 
intestinal epithelial cells during human intestinal development, resulting in the 
CSBS phenotype. Because CLMP is also expressed in the small intestine in 
adults,13 CLMP might have an important function in adult life. Potentially, CLMP 
may play a role in the intestinal elongation process that occurs during a person's 
lifetime (the length of the intestine in adults is 600 cm on average, ranging 
from 260 to 800 cm2) and in the intestinal adaptation process after surgical 
resection. T he effects on intestinal adaptation of growth factors such as growth 
hormone, keratinocyte growth factor, epidermal growth factor, and glucagon-like 
peptide-2 have been studied.1 7·2° Further studies will elucidate the role of CLMP 
in intestinal adaptation in adults and its therapeutic potential. 
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Supplementary Data 
Supplementary Table 1 .  Primer Sequences for CLMP Mutation Analysis 
Exon Forward Reverse PCR product size, bp 
AGGAGGCAACCATGTGGTTC ACAATCTCGATGGCCGACTG 580 
2 CACTTGCCCACGGGAACATC GCCACCACACCCAGCAATAC 443 
3 AAGGCAGGCTGAGAGTTACG CGAGGTGACCTCTGAATGTG 383 
4 AAACAGCACCACTGGAGTTG AATGGCAGTTCAGGAGGTTC 5 1 2  
5 GCATTACGGAATCTCAGCTCAG GGCCAGTCAATTGTTGAGTG 402 
6 AAACCTGCAAATACTCATTC AAGTGTTTGTTGAGGATAAG 455 
7 TACGAGGAAGCACCTATGAC GTGACTTGAGCTCCAATGAC 525 
PCR conditions: 35 cycles of denaturation at 95°C for 1 minute, annealing at 60°C for 1 minute and polymerization 
at 72°C for 1 minute. 
Supplementary Table 2. Primer sequences for Side-Directed Mutagenesis of pCMV6-CLMP­
GFP Vector 
Target Primer sequence, 5'? 3' Base pair change 
Forward primer CGCTACGTGTGGAGCCATGACATCTT AAAAGTCTT AG 
Reverse primer CT AAGACTTTT AAGATGTCATGGCTCCACACGTAGCG 
Supplementary Table 3. Morpholino Sequences 
Morpholino sequences, 5'? 3' 
151 translation blocking morpholino 
2nd translation blocking morphoilno 
5 mispair morphollno 
splice blocking morpholino 






Amino acid change 
Val125Asp 
Val1 25Asp 
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�plementary FiQll'8 2. Conservation and intronic deletion in family 3. (A) Hek293 cells were 
transfected with the pSPL3 vector only (V), the pSPL3 vector with the wild-type sequence of exon 
6 and its flanking sequences f,N), and the pSPL3 vector containing the sequences of exon 6 and 
the presumed splice site mutation (M). T he results of the amplification of the cDNA made of the 
mRNA of these transfected cells using the splice acceptor site and splice donor site primers are 
shown. T he exon has been trapped in the wild-type situation f,N), but has not been trapped in the 
mutated situation (M). T his means that the splice site mutation affects the splice donor site so 
that it is not recognized by the splicing machinery. (B) T he missense mutation found in patient 2-1 
affects a codon which is evolutionary highly conserved. In the figure it can be observed that this 
amino acid and all the surrounding amino acids are coloured red (labelled as good). Good indicates 
highly conserved, bad (blue) means not conserved. (C) A homozygous deletion surrounding SNP 
rs71 15102 in intron 1 was detected in patients 3-1 and 3-2. PCR yielded results for the parents (f: 
father, m: mother) as well as for the unaffected sibling (s) and for the control (c), but no PCR product 
was detected in the patients (p). Lane b (b= blanco, negative control) is a PCR without adding DNA. 
By using primers flanking the deletion (forward, 5'-AT T GGAGGATGT GACCT CT GAGT CT TAT GG-3' 
and reverse, 5'-GGCAGAGAAAGT GGGAAACCTATAGTMGC-3') the PCR product was expected 
to be approximately 5 kb for the normal situation. By using small sets of primer pairs surrounding 
SNP rs7115102 a region of around 1 kb could not be amplified in the patients. T herefore, the PCR 
product in the patients was expected to be around 4 kb. Because there is no PCR product from the 
patients' DNA at all, this is indicative of a more complex alteration than the simple deletion detected 
by the SNP array. 
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Abstract 
Loss-of-function mutations in CLMP have been found in patients with Congenital 
Short Bowel Syndrome (CSBS), suggesting that its encoded protein plays a major 
role in intestinal development. CLMP is a membrane protein that co-localizes 
with tight junction proteins, but its function is largely unknown. We expressed 
wild-type (WT)-CLMP and a mutant-CLMP (associated with CSBS) in human 
intestinal epithelial T84 cells that, as we show here, do not produce endogenous 
CLMP. We investigated the effects of WT-CLMP and mutant-CLMP proteins on 
key cellular processes that are important for intestinal epithelial development, 
including migration, proliferation, viability and transepithelial resistance. Our data 
showed that expression of WT-CLMP or mutant-CLMP does not affect any of 
these processes. Moreover, our aggregation assays in CHO cells show that 
CLMP does not act as a strong adhesion molecule. Thus, our data suggest that, 
in the in vitro model systems we used, the key processes involved in intestinal 
epithelial development appear to be unaffected by WT-CLMP or mutant-CLMP. 
Further research is needed to determine the role of CLMP in the development 
of the intestine. 
Introduction 
CLMP (coxsackie- and adenovirus receptor-like membrane protein) is a membrane 
protein that belongs to the CTX (cortical thymocyte marker in Xenopus) family 
of proteins.1 The precise function of CLMP is largely unknown although several 
suggestions have been made. For instance, it has been suggested that CLMP 
plays a role in immunological processes.1 -2 This is based on the fact that there 
is a high homology between CLMP and Junctional adhesion molecules (JAMs), 
both belonging to the CTX family of proteins. It is known that JAMs are important 
for transmigration of leukocytes to inflammatory sites.3 This hypothesis was 
further supported by the finding that TNFa, a pro-inflammatory cytokine, is able 
to regulate CLMP expression.2 In addition, it has been suggested that CLMP 
plays a role in cell-cell adhesion, based on the finding that it co-localizes with 
the tight junction proteins zonula occludens 1 (Z0-1)1 ·4 ·5 and occludin1. Moreover, 
transfection of human CLMP in Chinese Hamster Ovary cells (CHO) induces cell 
aggregation.1 ·6 In addition, transfection of human CLMP into Madin-Darby canine 
kidney (MOCK) epithelial cells induces transepithelial electrical resistance (TER), 
suggesting a role for CLMP in the junction-barrier function of intestinal epithelial 
cells.1 
Loss-of-function mutations in CLMP were identified in patients with 
Congenital Short Bowel Syndrome (CSBS).4 A missense mutation was identified 
(V1240) in one of these CSBS patients. Transient transfection of th is mutant­
CLMP (CLMP containing the missense mutation V124D) in CHO and T84 cells 
resulted in mislocalization of CLMP and in an increased cytoplasmic pool of Z0-
1.4 As tight junction proteins like Z0-1 play a role in cell proliferation,7•8 it has been 
suggested that loss-of-function of CLMP would probably affect proliferation of 
human small intestinal cells during foetal development and thereby causing a 
shortened small intestine.4 As the function of CLMP is still obscure, we aimed to 
gain a better understanding of the functional cellular role of CLMP. 
Materials and Methods 
Construction of Plasmids for Transient Transfection of Chinese Hamster Ovary 
Cells 
A pCMV6-CLMP-green fluorescent protein ( GFP) vector was obtained from 
Origene (Rockville, MD, USA). The CLMP missense mutation (c.730T>A, 
p.V124D) was introduced in this vector by site-directed mutagenesis (Strata gene, 
Amstelveen, Santa Clara, CA, USA) (for primer sequences see our previous 
publication).4 The wild-type (WT) and mutant cDNA were amplified using the 
primers CCGCC-Nhel, 5'-ATGTCCCTCCTCCTTCTCC-3', and GGGCGC-Xhal, 
5'-TCAGACCGTTTGGAAGGCTCTG-3'. The amplification was performed using 
Phusion High-fidelity DNA polymerase (Finnzymes, Helsinki, Finland). The PCR 
products were inserted into PCR 2.1-TOPO plasmid (lnvitrogen, Carlsbad, CA, 
USA). The PCR 2.1 Topo constructs were digested by Nhel and Xhal restriction 
enzymes and the fragments were cloned into the vector pCMV-internal ribosomal 
re-entry site ( IRES) coupled to eGFP (GFP-like protein). The clones were checked 
by direct sequencing. 
Construction of Viral Vectors for Transduction of T84 cells 
The pCMV-IRES-EGFP vectors, which were constructed as described 
above and contained both WT- and mutant cDNA (c.730T>A, p.V124D) 
of CLMP, were used as a template for amplification using the primers 
ACCA-Ncal-Myc, 5'- ATGTCCCTCCTCCTTCTC-3' and AACA-Xhal-
5'-TCAGACCGTTTGGAAGGCTCTG-3'. The PCR products were digested with 
Neal and Xhal and the fragments were cloned into the vector pEntr4. The clones 
were checked by digestion with Neal and Xhal and direct sequencing. The inserts 
were subsequently cloned into the vector plenti-CMV-Neo using lambda phage­
based site-specific recombination and the Gateway® recombination cloning 
technology (lnvitrogen). 
Production of LentMral CLMP 
For the production of the viruses, 2.6 x 106 HEK293 cells were grown in Dulbecco's 
modified Eagle medium (DMEM) supplemented with 10% heat-inactivated foetal 
bovine serum (FBS, lnvitrogen), 1 % antibiotic solution (penicillin-streptomycin, 
lnvitrogen) and 1 % sodium pyruvate. The cells were maintained at 37°C in a 
humidified atmosphere with 5% CO2. Co-transfection of both WT and mutant 
plenti-CMV-CLMP (V124D)-Neo with pVSV-G and pCMVdRB.1 was performed 
using the CaCl2 method. The cells were subsequently grown overnight. After 
24 hours the medium was changed to DMEM supplemented with 10% heat­
inactivated foetal bovine serum (FBS, lnvitrogen) and 1 % antibiotic solution 
(penicillin-streptomycin, lnvitrogen). After 24 and 48 hours, the medium containing 
the virus was collected and stored at 4 °C. Fresh medium was added to the cells. 
The collected medium was filtered using a polyvinylidene difluoride membrane­
based filter to remove HEK293 cells. 
Cell Culture 
Chinese Hamster Ovary (CHO) and human intestinal epithelial T84 cells 
were grown in commercially available alpha modification of eagle's medium 
and DMEM/F-12 (both lnvitrogen) respectively, supplemented with 4.5 mg/L 
L-glutamine, 10% heat-inactivated foetal bovine serum (FBS, lnvitrogen) and 1% 
antibiotic solution (penicil lin-streptomycin, lnvitrogen). The cells were maintained 
at 37°C in a humidified atmosphere with 5% CO2. 
Production of Stably Transduced CLMP T84 Cell Lines. 
For transduction the virus-containing solution and Hexadimethrine Bromide 
(Sigma; 4 mg/ml PBS) were added to T84 cells. The cells were then grown 
overnight at 37°C in a humidified atmosphere with 5% CO2 After 24 hours 
the medium was changed and the cells were grown till a confluency of 80% 
was reached. Transduction efficiency was checked by qPCR and Western blot 
analysis (see figure 1A). 
Real-time PCR 
Expression of CLMP in the transduced T84 cells was quantified with Quantitative 
Polymerase Chain Reaction (qPCR). Transduced T84 cells were lysed and mRNA 
was isolated according to the manufacturer's instructions (GeneJET™ RNA 
Purification Kit, Fermentas). The GAPDH gene was used as an internal standard 
for normalization. mRNA was used as a template to synthesise cDNA. PCR 
was performed using the primers (CLMP-F) 5'-GAAGGAAAGCTGTGTGGTG-
3' and (CLMP-R) 5'-CACTAT GCCT GT CACT GCT C-3' for CLMP and 
(GAPDH-F) 5'-CAT T T CCT GGTAT GACAACG- 3' and (GAPDH-R) 
5'-GT CCAGGGGT CT TACT CCT T - 3' for GAPDH and the following amplification 
program: 1 5  minutes 95C, 40 cycles 1 5  seconds 95°C, 1 minute 60°C. Each 
amp I if ication reaction was run in triplicate using 10 ng of cDNA, 1 50nM of both 
forward and reverse primers, and 1 x SYBR green master mix (ABCM-221 /A, 
Westburg, Leusden, the Netherlands) in a total volume of 1 O µL. T he results 
were analysed by StepOne1m software v2.2 and recalculated manually using the 
Comparative Cr Method. 
Western Blotting 
Cells were harvested with lysis buffer (100mM NaCl, 20mM T ris-HCI pH 7.6, 
T riton X-100 and protease inhibitors (Roche, Almere, the Netherlands)). After 
incubation on ice for 30 minutes, the lysate was centrifuged for 5 minutes at 
1 4,000 rpm at 4 °C. Protein concentrations were determined using the BCA 
protein assay (Pierce Biotechnologies, Rockford, IL, USA) and measured on a 
NanoDrop® ND-1000 (T hermo Scientific, Waltham, MA, USA). 
Protein extracts (40 µg) were resolved on an SDS/1 5% polyacrylamide gel, 
transferred on to a nitrocellulose membrane and blocked with dried milk powder 
in T ris-buffered saline with 0.1 %  Tween 20 for 1 hour at room temperature. T he 
membrane was then incubated with primary antibody rabbit polyclonal antibody 
for CLMP (anti-AP000926.6, Sigma-Aldrich) in 1 :500 dilution for 1 hour at room 
temperature. After 1 hour incubation with the secondary antibody goat anti­
rabbit conjugated with Horseradish peroxidase ( 1 :1 ,000; Bio-Rad, Hercules, 
CA, USA) at room temperature, the proteins were visualized using enhanced 
chemiluminescence reagent (Lumi-Light Western Blotting Substrate, Roche). 
Scratch/wound Healing Assay 
Control T 84 cells or T 84 cells expressing WT -CLMP or mutant-CLMP (V1 24D) 
were cultured on glass-bottom petridishes ( 1 .5 x 105 per dish) for 7 days after 
which they develop a polarized monolayer with functional tight junctions. T he 
dish was mounted on a microscope for live imaging. Monolayers were scratched 
with a micropipette and incubated in serum-deprived culture medium. After 24 
hours of incubation, the rate of migration into the scratch was determined and 
presented as µm/24 hours. Experiments were performed in triplicate and data 
were expressed as mean ± SD. 
BrdU Cell Proliferation Assay 
Cell proliferation was measured using a BrdU cell proliferation assay (Cell 
Signalling Technologies, Danvers, MA, USA) that detects 5-bromo-2'-deoxyuridine 
(BrdU) incorporated into cellular DNA during cell proliferation using an anti-BrdU 
antibody. T84 cells (1.5 x 105) (control, WT-CMP or mutant-CLMP (V124D)) were 
plated and cultured for 2 days. BrdU was included in the culture medium at a 
final concentration of 10 µM and added to a monolayer of T84 cells (control, 
WT-CMP or mutant-CLMP (V124D)). After 24 hours, the labelling medium was 
removed, cells were fixed and BrdU incorporation was measured according to 
the manufacturer's instructions. Experiments were performed in triplicate and 
data were expressed as mean ± SD. 
XTT Cell Viability Assay 
Cell viability was measured using an XTT cell viability assay kit (Cell Signalling 
Technologies), a colorimetric assay that detects cellular metabolic activities 
that only occur in viable cells. T84 cells ( 1.5 x 105) were plated and cultured 
for 2 days. The yellow tetrazolium salt XTT was then added to a monolayer of 
T84 cells (control, WT-CLMP or mutant-CLMP (V124D)) at a final concentration 
of 20 µg/ml. After 4 hours of incubation, the formazan dye that formed was 
quantified by measuring the optical density (OD) at wavelength 450 nm using 
a spectrophotometer. The OD measured at wavelength 690 nm was used as 
background reference. The specific OD was calculated by substracting the OD 
measured at wavelength 690 nm from the OD measured at wavelength 450 nm. 
Experiments were performed in triplicate and data were expressed as mean ± 
SD. 
Measurement of Transepithelial Electrical Resistance in Mono/ayer T84 Cultures 
T84 cells were grown on polycarbonate 24-wells Transwell filter inserts (Corning 
Costar, Corning, NY, USA) for 7 days. Transepithelial electrical resistance was 
measured using an epithelial Volt/Ohm-meter (World Precision Instruments, 
Sarasota, FL, USA). Experiments were performed in triplicate and data were 
expressed as mean ± SD. 
Transfection of CHO Cells for Aggregation Assays 
WT or mutant pCMV-CLMP (V124D)-IRES-EGFP was transfected into CHO 
cells (1.5 x 105) with Lipofectamine 2000 T ransfection Reagent (lnvitrogen) in 
a 1 :3 dilution, and transfection efficiencies were evaluated by measuring EGFP 
expression by flow cytometry (around 50% efficiency). 
Aggregation Assays 
T he bottoms of the wells of a 96-well plate were covered with semi-solid agar 
medium (100 mg Bacto-agar in 15 ml Ringer's salt solution) to prevent cell­
substratum adhesion. T hereafter, a single cell suspension was added and 
incubated at 37°C in a humidified atmosphere with 5% CO2 for 24 hours and 
48 hours. Aggregation was evaluated under an inverted microscope with a 4X 
objective and pictures were taken at both time points. 
Results 
Viral Transduction of T84 Cells 
T 84 colonic adenocarcinoma cells grow to confluent polarized monolayers that 
exhibit functional tight junctions and have been used extensively as a model 
to study intestinal tight junction integrity.9·11 We found that T 84 cells do not 
endogenously express CLMP (Figure 1), which makes this cell line a suitable 
model system to explore the effect of CLMP and CSBS-related CLMP mutants 
on epithelial functions related to the tight junction. For this, we stably transduced 
both WT -CLMP and mutant-CLMP (CLMP containing the missense mutation 
V124D). WT -CLMP and mutant-CLMP (V124D) were equally expressed in the 
transduced T 84 cells as measured by real-time PCR (see Figure 1A). This result 
was confirmed by Western blot (see Figure 1 B). 
CLMP does not Affect Migration of T84 cells 
To assess whether CLMP plays a role in intestinal cell migration, we performed 
a wound healing experiment. T 84 cell monolayers were wounded and incubated 
in serum-deprived medium for 24 hours. T here was no significant difference in 
. • 
the rate of directional cell migration (distance travelled/time unit) between the 
three groups (see Figure 2A). We concluded that overexpression of WT-CLMP 
or mutant-CLMP (V124D) does not affect the directed migration of T84 cells. 
CLMP does not Interfere with Proliferation of T84 cells 
Proliferation of control and WT-CLMP or mutant-CLMP (V124D) expressing cells 
was quantified by measuring BrdU incorporation. There was no difference in 
BrdU incorporation between the three groups (see figure 2B). These data show 
that overexpression of WT-CLMP or mutant-CLMP (V124D) does not interfere 
with T84 cell proliferation. 
CLMP does not Affect Cell Viability in TB4 cells 
To assess whether CLMP improved cell viability, we performed the in vitro XXT­
based Toxicology Assay. T84 cells (1.5 x 105) Were plated and cultured for 2 
days. After 4 hours of incubation with 20 µg/ml XTT, the specific absorbance 
was not significantly different between the three groups (see figure 2C). These 
data demonstrate that overexpression of WT-CLMP or mutant-CLMP (V124D) 
does not affect the viability of the T84 cells. 
CLMP does not Increase Transepithelial Electrical Resistance in T84 Cells 
Transepithelial electrical resistance is a measurement of ion flux over a polarized 
epithelial monolayer and can be used as a model for the junction-barrier function 
of tight junctions. Others have shown that overexpression of CLMP in MOCK 
cells, which do not express CLMP endogenously, increases the transepithelial 
resistance. We therefore assessed whether transfection of human CLMP into 
T84 cells influenced the transepithelial resistance. However, we observed no 
significant difference in transepithelial resistance between the control (not 
transduced) T84 cells, the T84 cells transduced with the WT-CLMP virus and 
the T84 cells transduced with the mutant-CLMP (V124D) virus (see Figure 2D). 
Thus, WT-CLMP and mutant-CLMP (V124D) do not increase or interfere with the 
transepithelial electrical resistance of a T84 cell monolayer. 
CLMP does not act as a strong cell-cell adhesion molecule 
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Figure 1. Expression of CLMP in T84 cells transduced with wild-type (WT)-CLMP, mutant-CLMP 
(V124D), RFP and an empty vector. There is no endogenous expression of CLMP in T84 cells 
(see the right lane (empty vector)). A. WT-CLMP and mutant-CLMP (V1 24D) mRNA were equally 
expressed in the transduced T84 cells as measured by real-time PCR. B. Western blots showed 
that WT-CLMP and mutant-CLMP (V1 24D) (at 41kDa) protein were equally expressed. The 1 00 
kDa band is an aspecific band derived from the vector: 
the missense mutation (V1 24D) on its ability to do so, we decided to perform 
a slow aggregation assay, using CHO cells that do not aggregate at all in this 
assay. As a positive control, we transfected CHO cells with a Cadherin 1 (CDH1) 
vector, Cadherin 1 is also called epithelial or E-cadherin which is a known cell­
cell adhesion protein, which resulted in large aggregates (see Figure 3). However, 
there were no significant differences between non-transfected and transient 
human CLMP (wild-type or mutant (V1 24D)) transfected CHO cells after 24 hours 
or 48 hours of incubation (see Figure 3). We concluded that CLMP does not act 
like CDH1 as a strong cell-cell adhesion molecule. 
Discussion 
Loss-of function mutations in CLMPwere found in CSBS patients.4 These patients 
have a congenital short small intestine with a mean length of 50 cm compared 
to a normal length of 250 cm at birth. CLMP is a trans-membrane protein and co­
localizes with the tight junction proteins zo-1 1 ,4,s and occludin.1 lmmunostaining 
on human embryos showed that CLMP was expressed in many tissues including 
the gut. Knock down experiments of the orthologue in zebrafish resulted in 
general developmental defects including an affected intestine. Goblet cells are 
normally present in the mid intestine in zebrafish (which resembles the small 
intest ine in humans}, and can therefore be used as a marker for this epithelial 
tissue. Since the goblet cells were absent in the morphant zebrafish, knock down 
of the orthologue of CLMP in zebrafish would probably result in the absence of 
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Figure 2. Overexpression of wild type (WT)-CLMP and mutant-CLMP (V124D) in human intestinal 
epithelial T84 cells does not affect wound healing/migration, cell proliferation, viability, and 
trans-epithelial electrical resistance. A. Cell monolayers were wounded and incubated in serum­
deprived medium for 24 hours. The rate of directional cell migration (distance travelled/time 
unit) and wound closure were determined. B. Proliferation was quantified measuring BrdU 
incorporation using a BrdU cell proliferation assay. There was no significant difference in the 
specific optical density (OD) (the measured OD at wavelength 370 nm minus the measured 
OD at wavelength 492 nm) between the three groups. C. Cell viability was estimated using an 
in vitro Toxicology Assay Kit XTT-based. XTT was added to the cells at a final concentration 
of 20 µg/ml. After 4 hours of incubation the OD was measured at 450 nm using the 690 nm 
absorbance as the background. (There was no significant difference between the three groups). 
D. T ransepithelial electrical resistance was measured in confluent cell monolayers cultured on 
Transwell filter inserts. 
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intestinal development, although its function is still largely unclear.4 However, it is 
known that transient transfection of human CLMP into human intestinal epithelial 
T84 cells showed CLMP localization at the cell-cell membrane contacts.4 It is 
also known that CLMP co-localizes with tight junction proteins, and is therefore 
claimed as a tight junction-associated protein. Because tight junction proteins 
play an important role in proliferation,7•8 we have suggested that loss-of-function 
of CLMP might affect proliferation.4 Moreover, it was shown that transfection of 
human CLMP into MOCK cells increases transepithelial resistance.1 Whether it 
is proliferation, or transepithelial resistance, or indeed another process in which 
CLMP plays a crucial role and that has impact on the pathophysiology of CSBS, 
is still unknown. 
To elucidate the function of CLMP we performed several functional 
assays using T84 cells as a model. As previously reported, transient transfection 
of human CLMP into T84 cells showed localization of WT-CLMP at the cell 
membrane and mislocalization of mutant-CLMP (V1240) in the cytoplasm.4 
Although others have shown that transfection of human CLMP into MOCK 
cells increases transepithelial electrical resistance,1 we did not observe any 
differences in the transepithelial electrical resistance in T84 cells. We cannot 
say whether this discrepancy is due to the use of distinct cell types (MOCK 
versus T84) or to the fact that CLMP is simply not involved in this process. 
MOCK cells are kidney cells derived from a seemingly normal adult female 
cocker spaniel. Many different strains of the MOCK cell line are available and 
the transepithelial resistance in these different strains differs depending on 
the tight junction proteins that are expressed.12 This illustrates that even in the 
same cell line, different results can be obtained. Unfortunately, Raschperger et 
al did not mention which strain of the MOCK cell line they used.1 T84 cells are 
human colon carcinoma cells that have been widely used to study intestinal 
epithelial function.9-11 We would therefore like to argue that T84 cells form a 
more representative model for studying the function of CLMP than MOCK cells. 
We reported earlier that the missense mutation in CLMP, which 
was identified in one of the CSBS patients, leads to CLMP cytoplasmatic 
mislocalization.4 To study whether this missense mutation would also affect the 
adhesion properties of CLMP, we performed a cell aggregation assay using a 
widely accepted protocol implemented by Boterberg et al (Metastasis Research 
B 
CDH1 
Figure 3. No significant difference was observed in cell aggregation between CHO cells 
transfected with and without CLMP (wild-type and mutant (V124D)). A. Mock, CHO cells that 
were not transfected. B. CHO cells transfected with CDH1.  C. CHO cells transfected with wild­
type-CLMP. D. CHO cells transfected with mutant-CLMP (V124D). 
Protocols).1 3 As a positive control we transfected CHO cells with cadherin  1, also 
called epithelial or E-cadherin, a cell-cell adhesion protein that is an important 
component of the adherens junction.14•15 In our assay, transfection of CDH1 
resulted in large aggregates ,  but we did not observe wild-type CLMP acting as 
a strong cell-cell adhesion protein. In the previous reports that claim that CLMP 
acts as an adhesion protein, the assays were performed differently. Raschperger 
et al used CAR as a positive control.1 Eguchi et al used low- and high-express ing 
CLMP stable transfected cell lines and observed a significant difference in the 
size of the aggregates.6 The incubati on time that Raschperger et al and Eguchi 
et al used in the aggregation assays was shorter, 60 minutes and 90 minutes 
compared to the incubation time of 24 hours and 48 hours we used in our 
experiments. Differences in the formation of aggregations might be found in a 
shorter time frame, while they probably become equal after a longer incubation 
time. This might well explain why we were not able to confirm the previous 
findings. However, when we compare our f igures with those of both Raschperger 
et al and Eguchi et al, we notice that the size of the aggregates we observed in 
CHO cells transfected with CDH1 was far bigger. In addition, the figures in the 
previous reports are much closer to our figures for the CLMP-transfected CHO 
cells than to our positive control, CHO cells transfected with CDH1. CLMP might 
have some adhesion capacity comparable with CAR, but based on our assays 
we have to conclude that CLMP is not a strong adhesion molecule like CDH1. 
Because CLMP co-localizes with tight junction proteins and tight junction 
proteins play an important role in proliferation,7•8 we thought that loss-of-function 
of CLMP might affect proliferation.4 However, in our proliferation assay in T84 
cells, we could not elucidate a role for CLMP in proliferation and based on our 
assays in T84 cells, CLMP also does not play a role in migration and cell viability. 
From our results we have to conclude that CLMP does not play a major 
role in cell-cell adhesion, nor does it affect migration, proliferation, cell viability 
and transepithelial electrical resistance in T84 cells. The fact that T84 cells do 
not express CLMP, but do form proper tight junctions, points to the conclusion 
that CLMP cannot be essential for tight junction formation. Thus, although CLMP 
co-localizes with tight junction proteins, its functi on is probably not directly 
related to the tight junction. More research is needed to better understand the 
function of CLMP and why loss-of-function mutations in CLMP cause Congenital 
Short Bowel Syndrome. 
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Abstract 
Purpose. Autosomal recessive Congenital Short Bowel Syndrome (CSBS) is 
caused by mutations in CLMP. No mutations were found in the affected males 
of a presumed X-linked CSBS family or in an isolated male patient. Our aim was 
to identify the disease-causing mutation in these patients. 
Methods. We performed mutation analysis of the second exon of FLNA in the 
two surviving affected males of the presumed X-linked family and in the isolated 
patient. 
Results. We identified a novel two-base-pair deletion in the second exon of 
FLNA in all these male patients. The deletion is located between two nearby 
methionines at the N-terminus of FLNA. Previous studies showed that translation 
of FLNA occurs from both methionines, resulting in two isoforms of the protein. 
We hypothesized that the longer isoform is no longer translated due to the 
mutation and that this mutation is therefore not lethal for males in utero. 
Conclusion. Our findings emphasize that Congenital Short Bowel Syndrome can 
be the presenting symptom in male patients with mutations in FLNA. 
Keywords: FLNA; short small intestine; mutation; chronic idiopathic intestinal 
pseudo-obstruction; synovial lipomatosis. 
Introduction 
Congenital Short Bowel Syndrome (CSBS) is characterized by a shortened small 
intestine and intestinal malrotati on. While the normal length of the small intestine 
at b irth is approximately 275 cms,1 patients with CSBS have a markedly shorter 
small intestinal length of around 50 ems, on average. CSBS has a high mortality 
rate within the first few months after birth, although some long-term survivors of 
CSBS have been reported.2-5 
CSBS is an inherited disorder. The identification of homozygous and 
compound heterozygous mutations in Coxsackie- and adenovirus receptor-Like 
Membrane Protein (CLMP) in CSBS patients confirmed an autosomal recessive 
pattern of inheritance in most affected families.6 However, no CLMP mutations 
were identified in one Italian family7·8 nor in an isolated German-American male 
(Table) who presented with Congenital Short Bowel Syndrome.5 In the affected 
family, only males developed the disease, consistent with an X-linked pattern of 
inheritance (Figure).8 
In the literature a family with X-linked Chronic Idi opathic Intestinal Pseudo­
obstruction (CIIP) has been described.9·1 0The patients in this family have very 
similar features to those seen in CSBS patients with mutations in CLMP, including 
a shortened small intestine. A two-base-pair deletion in the second exon of 
Filamin A (FLNA) (c.65-66delAC) was identified in this X-linked CIIP family. This 
deleti on is located between two nearby methionines at the N-terminus of FLNA. 
It was shown that translati on of FLNA can occur from either methionine in vitro 
and that the deletion only affects the longer form of FLNA.1 0  
We hypothesized that the longer form of FLNA is essential for normal 
small intestinal development and we therefore performed mutation analysis of 
the second exon of FLNA in the X-linked CSBS family and in the isolated male 
patient. 
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Figure.A Pedigree of the X-linked CSBS family_ B. Chromatogram showing FLNA exon 2 sequence 
around c.1 6-17delT C. Top: sequence of healthy family members, same as reference sequence. 
Middle: sequence of female carriers in the family; heterozygous for the c.16-17delT C mutation_ 
Bottom: sequence of the male CSBS patients carrying the c.16-17delT C mutation . 
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Materials and Methods 
Patients 
The presumed X-linked CSBS family was reported by Kern et al.2 As described in 
their case report, the patients in this family presented with bile-stained vomiting 
and diarrhoea, symptoms typically seen in Congenital Short Bowel Syndrome 
patients. The two patients in the Italian family who survived were included in our 
study. Patient 1 1 -6 was born with a small intestine of a total length of 60 ems. The 
family pedigree is presented in the figure. The isolated male patient (patient I, 
family 2) who presented with Congenital Short Bowel Syndrome was described 
by Siva et al; who emphasized the extensive nature of a rare arthropathy known 
as synovial lipomatosis.3 The measured small intestinal length of this patient 
was 90 inches (=228.6 ems) at age 15 (one-third of normal length). This patient 
is a long-term survivor and is over 40 years old. The arthropathy resolved 
spontaneously. 
Our study protocol was approved by the institutional and national ethics 
review committees at University Medical Centre Groningen (NL31708.042.10) 
and at Washington University School of Medicine. Written informed consent was 
obtained from all the study participants. 
Genetic Analysis 
Genomic DNA was isolated from peripheral whole-blood lymphocytes by 
standard procedures. Mutation analysis of the exonic and flanking intronic 
regions of the second exon of FLNA (NG_011506.1) was performed using the 
primers FLNA forward, 5'-CGCAACCTCTGCTCCCTGCC-3', and FLNA reverse, 
5'-GCGCCACCGACACGTTCTCA-3'. PCR was performed as follows: 35 cycles 
with 100 nanogram of genomic DNA at 95°C for 1 minute, at an annealing 
temperature of 55°C for 1 minute and then at 72°C for 1 minute. This was 
accomplished in two patients of the family and their unaffected relatives, in the 
isolated male patient (patient I ,  family 2) and his mother, and in 92 controls of 
Caucasian ethnicity. 
FLNA-mutations 1n maie CSBS patients __ , - - 71 ,r 
, .. , .• � ...... · ... ·,; ·•-, •-.... .:-: i·  -. �J ,•• . . .. � "  -
Table. Clinical data on the X-linked Congenital Short Bowel Syndrome patients. 
Family Patient Ethnicity Sex Length small bowel Other features Mutation 
1 11-6 Italian Male 60 ems at birth Nil e.16-17delCT 
111-6 Italian Male Unknown Nil e.16-17delCT 
(ref 7 and 8) 
2 1 German-American Male At age 15:  228,6 ems Synovial lipomatosis e.16-17delCT 
(ref 5) 
Results 
We identified a two-base-pair deletion (c.1 6-17delTC) in the two surviving 
affected males in the family and also in the isolated male patient (Figure). We 
confirmed co-segregation of the 2-bp deletion in the X-linked family and showed 
that all the obligate carriers were heterozygous for this delet ion. Because the 
mother of the isolated male patient did not carry the deletion, we concluded 
that his mutation had occurred de novo. Moreover, this mutation was absent in 
92 controls and is not reported in any SNP database or in the exome sequence 
variant database (http://evs.gs.washington.edu/EVS/). 
The c.1 6-17delTC deletion results in a frameshift and a premature stop 
codon at amino acid 103. In the predicted protein, only the first six amino acids 
are retained, which are identical to the wild-type f ilamin A. They are followed by 
97 different amino acids. As the c.16-17delTC mutation is located between the 
first and second methionine, it likely has a similar effect to the c.65-66delAC 
mutation (found in CI IP)10 that results in loss of only the long form of FLNA. 
Discussion 
Mutations in FLNA are associated with a wide spectrum of disorders, including 
periventricular nodular heterotopia, otopalatodigital syndromes types 1 and 2, 
frontometaphyseal dysplasia and Melnick Needles syndrome, and X-linked cardiac 
valvular dystrophy.11·1 3  Our findings add Congenital Short Bowel Syndrome to this 
list as a possible present ing phenotype in male patients with a mutation in FLNA. 
We therefore emphasize the importance of FLNA in intestinal development. The 
index patient of the family described by Gargiulo et al developed asymmetrical 
spastic diplegia and an abnormal intermediate signal in the peritrigonal white 
matter was seen on MRl.10 We cannot exclude central nervous system involvement 
in our patients because no MRI brain scans were available. However, they did 
not have any clinical neurological abnormalities like seizures or spasticity; not 
all patients with mutations in FLNA have central nervous system involvement. 
The mother of the proband described by Kapur et al did have a duplication of 
the first 28 exons of FLNA, but had a normal cranial MRl.14 
In addition to Gargiulo et afs finding of a 2-bp deletion in FLNA in one 
male CIIP patient, Kapur et al reported FLNA mutations in patients with CIIP.10·1 4  
They identified a partial duplication of the first 28 exons of FLNA in one family 
and a nonsense mutation (c.7021C> T; Q2341X) in exon 43 in another patient. 
However, these patients were diagnosed with multiple congenital anomalies, of 
which a congenital short bowel was only one feature.14 These findings support 
our hypothesis that FLNA is important for normal small intestinal development. 
As the mutations in the second exon are located between the first 
two methionines, they probably act as mild mutations, conserving the reading 
frame encoding the short isoform, associated with a rather mild phenotype. The 
mutations identified in the patients reported by Kapur et al were much more 
severe, explaining their more severe phenotype. 
Our finding raised the question whether CSBS patients with a mutation 
in the second exon of FLNA and CSBS patients with mutations in CLMP have 
the same phenotype. Clearly, the congenital short bowel is a feature they have 
in common, but also pseudo-obstruction has been described in CSBS patients 
with mutations in CLMP. Therefore, the bowel tissue of CSBS patients has been 
studied to determine if there is an abnormality of the enteric nervous system 
underlying the reduced bowel movements. Although the bowel wall in CSBS 
patients seems to be macroscopically normal, Tanner et al described abnormal 
histology of the bowel wall revealed by silver staining, in which there were too 
many neurons in the ganglia.15 The neuronal nuclei showed clumped chromatin, 
which is characteristic of neuroblasts. They observed that the intrinsic argyrophil 
ganglia were absent or much reduced in number, and argued that these 
histological findings might cause the motility abnormalities described in their 
patient as well as in other cases.15 In addition, Schalamon et af6 observed an 
abnormal bowel wall with signs of neuronal intestinal dysplasia in a patient from 
• • 
a consanguineous Turkish family, in whom a truncating homozygous mutation in 
CLMP was detected.6 In other cases, no abnormalities of the nerve plexus were 
observed on routine histology or by acetylcholinesterase staining.17·1 8  However, 
histology specimens were not available for all cases. 
To conclude, the clinical features of CSBS patients with FLNA mutations 
conserving the short isoform and CSBS patients with mutations in CLMP are 
very similar. Both have a congenital shortened small intestine and malrotation. In 
addition, all CIIP patients described with FLNA mutations have a congenital short 
bowel as a common feature. Male CSBS patients with either missense mutations or 
distal truncating mutations in FLNA have in general multiple congenital anomalies, 
and not only a congenital shortened small intestine. However, the male patients 
in our study and the male patient described by Gargiulo et al presented with a 
gastrointestinal phenotype, including malrotation, a shortened small intestine 
and pseudo-obstruction, and all have a 2-bp deletion in the second exon of 
FLNA.10 Thus, starting with screening exon 2 of FLNA is therefore recommended 
in male patients presenting with CSBS without mutations in CLMP. If no mutation 
is found in the second exon of FLNA, screening the entire FLNA gene might 
reveal another, more distal, non-truncating mutation. In male patients with CSBS 
and multiple major congenital anomalies, it is worth screening the entire FLNA 
gene for mutations. A family history of features associated with FLNA mutations, 
like periventricular nodular heterotopia and cardiac valvular dystrophy can also 
point to FLNA mutations. Furthermore, as FLNA mutations have not been found 
in patients with only pseudo-obstruction, we argue that a diagnosis of CSBS 
rather than CIIP, with or without central nervous system involvement, should 
drive additional genetic screening for mutations in FLNA in male patients. These 
data also suggest that FLNA could be seen as the underlying gene for CSBS 
rather than for CIIP.10 As mutations in either FLNA or CLMP can explain CSBS, 
further research is needed to understand a possible interaction of their gene 
products. 
We do not know whether FLNA and CLMP are directly linked or are part 
of the same protein network. Raschperger et al showed that CLMP co-localizes 
with actin filaments.1 9 They speculated that CLMP interacts with a protein that 
directly binds to actin filaments, which would bring CLMP to the tight junction 
by anchoring CLMP in the actin cytoskeleton. They suggested that Z0-1 could 
be such an interacting protein. As FLNA also binds to actin filaments, we can 
speculate that FLNA is the link between CLMP and the actin cytoskeleton. It 
is known that FLNA interacts with other trans-membrane proteins like integrin 
beta and the cystic fibrosis trans-membrane conductance regulator (CFTR).20 
There is also supportive evidence that FLNA plays a role in anchoring trans­
membrane proteins in the cell membrane. It has been shown, for example, that 
for the expression of CFTR on the cell membrane, the interaction of CFTR 
with FLNA is important.20 Therefore, we might suspect that FLNA plays a role 
in the internalization of CLMP in the plasma membrane as well. It can be 
speculated that the mutations in FLNA influence the expression of CLMP on 
the plasma membrane. Further research is needed to determine whether CLMP 
and FLNA do indeed interact in the same protein network and, if so, which other 
proteins are involved in this network. We cannot exclude that different pathways 
underlie X-linked CSBS and autosomal recessive CSBS, with different disease 
mechanisms leading to a similar disease phenotype. 
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Abstract 
Here, we report a female patient who presented with persistent pulmonary 
hypertension of the newborn and dysmorphic features. She died at the age of 
one month despite extracorporeal membrane oxygenation. At autopsy, intestinal 
malrotation and a short small intestine were identified. Array-CGH was performed 
because multiple congenital abnormalities were seen and this revealed a normal 
female karyotype. The CLMP and FLNA genes were screened for mutations 
because of the congenital short small intestine. Subsequently, because she also 
showed dysmorphic features that can be seen in Noonan syndrome and its 
related syndromes, Cardio-Facio-Cutaneous syndrome and Costello Syndrome, 
molecular genetic testing of the genes known in these syndromes was also 
performed. However, no mutations were identified. The unusual presentation 
of Congenital Short Bowel Syndrome (CSBS) in this female patient presenting 
with pulmonary hypertension without alveolar capillary dysplasia suggests a new 
disease entity. Furthermore, it shows that next to CLMP and FLNA, there are 
probably additional genes involved in CSBS. 
:I 
Background 
Here, we report a female patient who presented with persistent pulmonary 
hypertension and dysmorphic features. Despite treatment with extracorporeal 
membrane oxygenation, the patient's condition deteriorated and treatment was 
discontinued. She died at the age of one month. At autopsy, a shortened small 
intestine and malrotation of the bowel were observed. The unusual presentation 
of Congenital Short Bowel Syndrome in this female patient presenting with 
pulmonary hypertension without alveolar capillary dysplasia suggests a new 
disease entity. 
Case presentation 
A baby girl was born after labour was induced for prolonged rupture of membranes 
at 39 + 5 weeks. She was the second child, first girl, of non-consanguineous 
Caucasian parents. The family history was negative for congenital anomalies 
and mental retardation, except for a third-degree female relative with a neural 
tube defect. Pregnancy history was negative for teratogenic or mutagenic factors. 
Her birth weight was 3.5 kg and the Apgar scores were 4, 6, 6 at 1, 5, and 1 O 
minutes, respectively. Prenatally, polyhydramnios and an absent stomach bubble 
were observed and esophageal atresia was therefore suspected. However, 
this could not be confirmed after birth. Because of respiratory insufficiency, 
she was intubated and mechanically ventilated, and transferred to the neonatal 
intensive care unit. Because of severe oxygenation problems due to persistent 
pulmonary hypertension of the newborn, she was transferred to a tertiary centre 
for extracorporeal membrane oxygenation (ECMO) after maximal conventional 
therapy failed to help. 
She showed dysmorphic features: a high forehead, a short webbed 
neck, a low posterior hairline, an inter-nipple distance of 9.5 cm (p75-p97), and 
slightly posterior-rotated ears. In addition, the second and third toes were long 
compared to the fourth and fifth toes. Brain MRI, renal echography and total body 
X-rays showed no abnormalities. Furthermore, metabolic screening excluded 
Carbohydrate-deficient glycoprotein syndrome (CDG), Gaucher syndrome, and 
Niemann Pick A+B syndrome. After an uneventful 6 days veno-venous ECMO-run, 
she was managed with conventional therapy. Sildenafil was started because of 
. • 
relapse of pulmonary hypertension. A chest tube was inserted for chylous pleural 
effusion which was managed with total parenteral nutrition and minimal enteral 
feeding. The pulmonary hypertension deteriorated despite optimal treatment. It 
was therefore decided to discontinue treatment and she died shortly afterwards, 
at the age of 1 month. The parents gave consent for an autopsy. 
At autopsy the girl weighed 4160 gram (0 / +1  SD), her length was 55.5 
cm (0 / +1 SD) and her head circumference was 39.5 cm (+2 SD). On internal 
examination, non-chylous pleural effusion was found. The left lung consisted of 
two lobuli and the right lung of four lobuli. On microscopy pre-acinar and acinar 
arteries showed medial hypertrophy. The alveolar architecture was normal. 
The alveolar interstitium was widened and showed type 2-cell hyperplasia. In  
addition, a moderate chronic inflammatory infiltrate was noticed with congested 
capillaries. This histology is compatible with pulmonary hypertension due to 
persistent pulmonary hypertension of the newborn. No signs of pulmonary veno­
occlusive disease, pulmonary capillary haemangiomatosis, or alveolar capillary 
dysplasia were observed. The heart showed a situs solitus of the atria with 
concordant atria-ventricular and ventriculo-arterial connections. No structural 
abnormalities were noticed. The right atrium was dilated; the right ventricle was 
dilated and apex-forming. The oval foramen was only partially closed by an 
incompletely developed flap valve. The ductus arteriosus was patent. Abdominal 
examination showed mild chylous ascites. The ligament of Treitz was right­
sided. The small intestine was located at the right sight of the abdomen with a 
narrow mesentery. The colon was located at the left side of the abdomen with 
a long mesentery. The ileocecal junction was lying free in the abdomen without 
fixation. The length of the small intestine was 98 ems (in a normal newborn this 
would be approximately 310 ems, on average) and the length of the colon was 
52 ems (normally approximately 45 ems, on average). 
Differential diagnosis 
No clear cut disease entity fits the disease phenotype as observed in this patient. 
Because multiple congenital abnormalities were seen, a chromosomal syndrome 
was considered and array-CGH was performed. At autopsy a congenital short 
small intestine was observed, so we performed mutation analysis for the genes 
known to be related to Congenital Short Bowel Syndrome, namely CLMP and 
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FLNA.1 •2 
Due to her dysmorphic features, we considered Noonan Syndrome and its 
related syndromes, Cardio-Facio-Cutaneous syndrome and Costello Syndrome. 
The phenotypic features in these syndromes overlap which can be explained by 
the fact that mutations are found in genes which are all involved in the RAS-ERK 
pathway that regulates cell differentiation, prol iferat ion and apoptosis.3 Features 
that supported the diagnosis of Noonan syndrome were a low posterior hairline, 
a webbed neck, a high inter-nipple distance, the abnormal appearance of the 
ears, and pulmonary hypertension with pleural effusion. However, the absence 
of pulmonary valve stenosis, hypertrophic cardiomyopathy and/or hypertelorism 
argues against this diagnosis. 
Additional arguments for the diagnosis of Cardio-Facio-Cutaneous 
syndrome were the observation of polyhydramnios, a high forehead, and a large 
head circumference. Intestinal malrotation has been described in a child with 
Cardio-Facio-Cutaneous syndrome, although this diagnosis was not confirmed 
by molecular testing.4 However, our patient did not have a congenital heart 
disease or cutaneous capillary malformations. 
Polyhydramnios and a large head circumference are also features of 
Costello syndrome, although her birth weight was normal and no skin anomalies 
were seen. 
Investigations 
Array-CGH (Agilent 180 K) showed a normal female karyotype. Because 
Congenital Short Bowel Syndrome was observed at autopsy, sequence analysis 
for FLNA and CLMPwas performed.1 -2 Molecular genetic testing was performed for 
the genes involved in Noonan, Costello and Cardio-Facio-Cutaneous Syndromes: 
PTPN1 1, S0S1, RAF1, KRAS, NRAS, SHOC2, CBL,HRAS, BRAF,MAP2K1 and 
MAP2K2. However, this did not reveal any mutati ons. 
Discussion 
Here, we report a female patient who presented with persistent pulmonary 
hypertension of the newborn, dysmorphic features and who also proved to have 
Congenital Short Bowel Syndrome. 
The main causes of pulmonary hypertension in children are persistent 
pulmonary hypertension of the newborn and pulmonary hypertension related to 
congenital heart diseases.5 Normally, pulmonary vascular resistance decreases 
after birth, causing an increased pulmonary blood flow and closing of the oval 
foramen and the ductus arteriosus. The increased p02 in the alveoli and the related 
increased arterial p02 and decreased pC02 cause lowering of the pulmonary 
vascular resistance. In persistent pulmonary hypertension of the newborn this 
process is disturbed. There are many causes for this, such as perinatal asphyxia, 
septicemia, meconium aspiration syndrome, pulmonary hypoplasia, hypoglycemia, 
hypothermia and hyperviscosity. If the pulmonary vascular resistance does not 
decrease, the pulmonary blood flow will not increase and the gas exchange will 
be impaired, resulting in hypoxia. Because of the high vascular resistance in 
the lungs, blood will shunt through the oval foramen and the ductus arteriosus. 
Treatment of the impaired oxygenation is mechanical ventilation and sedation. 
In addition, inotropics and vasodilating agents like nitrogen oxide can be given. 
If this treatment is insufficient, extracorporal membrane oxygenation (ECMO) 
is the last treatment option.6 Pulmonary hypertension can also be caused by 
ventricular septal defects, atrio-ventricular-septal defects and a patent ductus 
arteriosus. Increased blood flow or increased vascular resistance, or both, can 
be the underlying mechanisms involved in the pathophysiology of the pulmonary 
hypertension.6 Finally, bronchopulmonary dysplasia can also lead to pulmonary 
hypertension but is often missed. Pulmonary hypertension is often related to 
genetic syndromes, of which trisomy 21 is the most common.5 
Thus, pulmonary hypertension may be due to many causes and it 
does not have to be inherited or genetic. However, in this patient we also saw 
dysmorphic features as well as pulmonary hypertension, pointing to a genetic 
syndrome. Because no clear cut disease entity fitted the observed phenotype, 
a chromosomal syndrome was considered. We performed array-CGH, which 
showed a normal female karyotype. At autopsy a congenital short small intestine 
was observed, which is believed to be an inherited disease. 
Patients with Congenital Short Bowel Syndrome (CSBS) usually present 
within a few days after birth with bile-stained vomiting, diarrhoea, and failure 
to thrive. Occasionally, a shortened small intestine and malrotation is detected 
later in life when an exploratory laparotomy is performed for significant 
gastrointestinal complaints.7 While the mean length of the small intestine at birth 
is normally 250 ems, patients with CSBS are born with a small intestine of 50 
ems, on average. Other gastrointestinal anomalies that are observed in CSBS 
patients are the absence of the appendix,0-1 O volvulus,1 1 ·1 2  a shortened colon,8•1O,1 3 
and hypertrophic pyloric stenosis. Recently, we have identified mutations in 
Coxsackie- and adenovirus receptor-Like Membrane Protein (CLMP, also called 
adipocyte specific adhesion molecule [ASAM],- MIM-6 11693) and Filamin A 
(FLNA; MIM-300048) in CSBS patients.1-2 
The pathology results showed that the lung abnormalities were consistent 
with a persistent pulmonary hypertension of the newborn, and an open foramen 
ovale and a patent ductus arteriosus were found. A patent ductus arteriosus 
has been described in patients with Congenital Short Bowel Syndrome.14·1 5 In 
one case, a patent ductus arteriosus was found at autopsy.14 In another case, 
a systolic murmur was observed on physical examination and an ECG showed 
left ventricular hypertrophy, together with the findings on the X-ray, a patent 
ductus arteriosus was suspected. This patient developed cardiac failure at the 
age of 6.5 months and was treated with digitalis until surgical correction of 
the patent ductus arteriosus could be performed at the age of 20 months.14 In 
addition, Royer et al reported a CSBS patient who presented with gastrointestinal 
problems and a systolic murmur, suggesting a patent ductus arteriosus.1 5 A 
male patient was also reported with intestinal pseudo-obstruction and multiple 
congenital anomalies, including intestinal malrotation, a short small intestine, 
patent ductus arteriosus and periventricular nodular heterotopia. A duplication 
of the first 28 exons of FLNA was identified in this patient and in his nephew, 
who was stillborn at the age of 33 weeks and was also diagnosed with multiple 
anomalies, including a malrotated short small intestine.1 6 So mutations in FLNA 
have been described in male patients with Congenital Short Bowel Syndrome 
and with multiple congenital anomalies including a patent ductus arteriosus. 
Furthermore, mutations in FLNA were found in patients with Congenital 
Short Bowel Syndrome without a patent ductus arteriosus. A two-base-pair 
deletion in the second exon of FLNA was identified in a male patient with 
chronic idiopathic intestinal pseudo-obstruction, a short small bowel, intestinal 
malrotation, pyloric hypertrophy and an ileal volvulus.17•1 8  In addition, we identified 
a novel two-base-pair deletion in the second exon of FLNA in an X-linked CSBS 
family and an isolated male CSBS patient.2 A nonsense mutation c.7021 C> T was 
identified in FLNA in another male patient with multiple congenital anomalies, 
including a short small intestine.1 6 
Finally, pulmonary disease has been reported in patients with FLNA 
mutations but without CSBS.1 9•20 A male patient with a mosaic nonsense 
mutation in FLNA has been described who presented with periventricular nodular 
heterotopia, a patent ductus arteriosus that was ligated after five days and 
severe congenital lung disease. The lung disease included bilateral atelectasis, 
lung cysts, tracheobronchomalacia, pulmonary arterial hypertension, and long­
term oxygen dependency. Pan-pulmonary emphysema and reduction of bronchial 
cartilage was seen on histology. A congenital short small intestine was not 
reported in this patient, but he did have a supra-umbilical hernia and needed 
nutritional support.1 9  The association of a mutation in FLNA and lung disease 
was confirmed in a female patient with a missense mutation c.220G>A. She 
presented with periventricular nodular heterotopia, cardiovascular abnormalities, 
including an atrial septal defect and coarctation of the aorta and lobar emphysema 
of the right middle pulmonary lobe with bronchomalacia. Emphysema without 
inflammation was seen on histology.20 
Thus, mutations in CLMP and FLNA were considered. Since patients 
with CSBS and mutations in CLMP do not usually have additional congenital 
anomalies, but a restricted gastrointestinal phenotype, mutations in FLNA were 
more likely to underlie the disease entity in this patient. Although the patient was 
female, mutations in FLNA were still considered because, as mentioned above, 
mutations in FLNA have been reported in both male and female patients with 
a patent ductus arteriosus.1 6•1 9• 2 1 ·23 However, sequence analysis of both FLNA 
and CLMP and array-CGH revealed no mutations, nor homozygous deletions or 
duplications around FLNA and CLMP. 
The female patient we report here had an unusual presentation in that 
other CSBS cases reported with a patent ductus arteriosus presented with 
gastrointestinal problems rather than with pulmonary hypertension. In addition, 
as far as we know, a short neck and a low posterior hairline have never been 
described in patients with Congenital Short Bowel Syndrome. We therefore 
performed molecular genetic testing for the genes involved in Noonan Syndrome 
and its related disorders because these syndromes often show features such as 
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a low posterior hairline, webbed neck, and pulmonary hypertension with pleural 
effusion. However, no mutations were identified in these genes. 
One candidate gene that we considered for our patient was FOXF 1. 
Pulmonary hypertension in association with alveolar capillary dysplasia and 
gastrointestinal malformations has been reported in patients with FOXF1 
mutations.24 Patent ductus arteriosus and bilobed right lung were also described 
in such patients. One female patient with a frameshift mutation in the second 
exon of FOXF1 was diagnosed with a congenital short bowel, malrotation and 
a small omphalocele in addition to alveolar capillary dysplasia.24 However, no 
alveolar capillary dysplasia was observed in our patient, and we therefore did 
not screen FOXF 1 for mutations. 
In conclusion, this is a case report of an unusual presentation of 
Congenital Short Bowel Syndrome in a female patient presenting with pulmonary 
hypertension without alveolar capillary dysplasia. This suggests a new disease 
entity and shows that more genes might be involved in Congenital Short Bowel 
Syndrome. 
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Abstract 
Congenital short bowel syndrome (CSBS) is a rare gastrointestinal disorder. While 
the mean length of the small intestine at birth is normally 250 ems, patients 
with CSBS are born with a small intestine of 50 ems, on average. Due to the 
much reduced small intestinal surface, they suffer from severe malnutrition. 
CSBS patients present within a few days after birth with bile stained vomiting 
and diarrhoea or later with failure to thrive. Occasionally, a shortened small 
intestine is detected later in life when an exploratory laparotomy is performed for 
significant gastrointestinal complaints. Often a barium contrast X-ray will point 
to the diagnosis, but it has to be confirmed by exploratory laparotomy. Because 
families with several affected family members have been described, it has been 
suggested that CSBS has a genetic basis. Recently, mutations in CLMP have 
been found to be the cause of the recessive form of CSBS and mutations in FLNA 
cause the X-linked form of the disease. We discuss hypotheses on the disease 
pathology as well as how the recent genetic findings can help to understand the 
cause of CSBS. 
Introduction 
Congenital Short Bowel Syndrome is a heritable gastrointestinal disorder, first 
described by Hamilton et al in 1969.1 For many years the underlying genetic 
cause of the disease was unknown. Recently, mutations in CLMP were identified 
to be the cause of the autosomal recessive form of the disease2 and mutations 
in FLNA as the cause of the X-linked form of the disease3• This review describes 
the clinical aspects, the recent genetic findings, and the aetiological aspects of 
this gastrointestinal disorder. 
Clinical presentation 
Patients with congenital short bowel syndrome often present with bile-stained 
vomiting and diarrhoea or failure to thrive. They usually present within a few days 
after birth, but the diagnosis has sometimes been made in patients as old as 15 
years.4 Patients suffer from ma I absorption due to the reduced absorptive surface 
of the small intestine.5 As these patients are also diagnosed with malrotation of 
the bowel, they are likely to have a general developmental defect of the bowel. 
The cecum is often positioned in the left upper quadrant of the abdomen close 
to the splenic flexure.1 ·6-1 0 Nonrotation has also been observed, in this case 
the cecum is located in the lower left quadrant of the abdomen.1 1  Although 
radiography can be suggestive for a shortened bowel, the diagnosis is usually 
confirmed by laparotomy. While the small intestine is normally around 250 ems in 
neonates, in CSBS patients its length is 50 ems on average. The appendix was 
absent in three reported patients,5•7•1 2  and volvulus was found in four patients.1 3·14 
In a few cases not only the small intestine, but also the colon was shortened.5•7• 
1 2·1 5 Another gastrointestinal anomaly that has been described in ten CSBS 
patients is hypertrophic pyloric stenosis.1 0·1 3·1 6- 19 It has been suggested that 
hypertrophic pyloric stenosis is not part of the general developmental defect 
of the gastrointestinal tract, but is rather a physiological finding that is a result 
of the remnant small intestine attempting to slow down the gastric emptying to 
improve absorptive capacity. 
The only extra-intestinal finding described in three CSBS patients is a 
patent ductus arteriosus.1 6•18 CSBS patients have a normal intellectual ability.20•21 
Although most authors did not report any dysmorphisms, Ordonez et al 
reported minor dysmorphic features of ears, nose and digits. T he ears were 
prominent, cup-shaped and the attached lobes were small, the nasal bridge 
was prominent, and the digits were long.9 The patient described by De Backer 
et al had dysmorphic ears and micrognathia and a balanced translocation of 
chromosome 2 and chromosome 11  (46,XX,t(2,11 )(q32.2, p12)) was detected.22 
Treatment management and outcome 
CSBS patients often need total parenteral nutrition for long-term survival and in 
some cases this has to be continued for the first two years of life.6·9 Oral feeding 
can be introduced gradually. Infection and other life-threatening complications 
of parenteral nutrition such as liver failure have to be managed carefully.16 
None of the CSBS patients described in the literature had had a small bowel 
transplantation. However, this procedure can be considered for CSBS patients 
who have recurrent sepsis or other complications of parenteral nutrition. It has 
been recommended that CSBS patients should be managed in a multidisciplinary 
manner in a centre specializing in the care of children with intestinal failure.9 
Only a quarter of the reported CSBS patients survived for more than one 
year (see Table), most CSBS patients die of starvation or sepsis within the first 
few days after birth. T he central venous catheters that are used for the supply of 
parenteral nutrition, in combination with their malnutrition state, leads to a high 
risk of developing sepsis, although the outcome is seen to be better in more 
recent case reports, suggesting that the care around parenteral nutrition has 
improved. 
T he functioning of the remnant small intestine of CSBS patients improves 
with time, both in length and absorption capacity, leading especially to better 
absorption of fat and vitamin B12.1 ·6·14 T he weight and height of CSBS patients 
are often below the 50th percentile,1·6·16·21 ·23 but the nutritious outcome is often 
normal.6,9 ,14,24 
Genetics 
Familial occurrence of CSBS was described in the very first case report of 
Hamilton et al. in 1969.1 T hey described a CSBS patient with French-Canadian 
parents who were not related and who had five daughters, of whom two were 
diagnosed with CSBS. One sibling died at the age of 1 month and 1 week prior 
. � 
Figure. The development of the intestine in human beings 
to death a laparotomy had shown a small intestine of 30 ems in length.1 More 
case reports followed and a familial occurrence was described in around 60% 
of the cases published in the literature, often with respect to affected siblings. In 
around 25% of the cases the parents were consanguineous (see Table). It has 
therefore been suggested by several authors that genetic factors are involved 
in CSBS and, because CSBS had been described in siblings of both sexes and 
in consanguineous families, an auto soma I recessive pattern of inheritance was 
proposed by many of them.6•10•18.2o.25-2a However, in some families only boys were 
affected, so an X-linked pattern of inheritance was suggested by others.16•14•19•29 
Chromosomal abnormalities 
Most CSBS patients have a normal karyotype, only two CSBS patients have 
been described with chromosomal abnormalities. Hou et al reported a female 
patient with multiple congenital anomalies including a congenital short bowel, 
malrotation, a patent ductus arteriosus, in addition to major malformations like left 
upper amelia, dextrocardia and asplenia. In this girl chromosomal investigation 
showed a mosaic pattern with complex rearrangements of chromosome 4: 85% 
of the peripheral lymphocytes showed a normal female cell line (46,XX), while 
1 2% of the cells showed a pattern with one normal chromosome 4 and a ring 
chromosome 4 (46,XX-4,+r(4)(p16-q22.3). The ring caused a deletion of the long 
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arm of chromosome 4. Approximately 4% of the cells had a pattern with a partial 
trisomy of chromosome 4, one normal chromosome 4, one ring chromosome 4 
and one chromosome 4 with the same deletion of the long arm of chromosome 
4 (47,XX,4,+r(4)(p16-q22.3),+del(4)(pter-q22.3:)).30 De Backer et al described a 
patient with a de novo balanced translocation between chromosome 2 and 11  
(46,XX,t(2,11)(q32.2,p12)). Interestingly CLMP, the gene involved in autosomal 
recessive CSBS (see next section), is located on chromosome 11 ,  but it is not 
in the proximity of this translocation.22 
Loss-of-function mutations in CLMP cause recessive CSBS 
In seven CSBS patients from five different families, different homozygous and 
compound heterozygous loss-of-function mutations have been identified in the 
gene encoding for the Coxsackie- and adenovirus receptor-Like Membrane 
Protein (CLMP).2 CLMP, located on chromosome 11q24.1, encodes a 
transmembrane protein that co-localizes with tight junction proteins and acts as 
an adhesion molecule.2·31 It is expressed in the intestine during different stages 
of human development and knock down of the orthologue in zebrafish resulted 
in developmental defects, including some of the intestine of the zebrafish. As 
tight junction proteins play an important role in proliferation,32·33 it has been 
hypothesized that loss-of-function of CLMP results in less proliferation of the 
small intestinal cells during human development, resulting in a shortened small 
intestine at birth.2 
The reported length of the small intestine of patients with mutations 
in CLMP is 30 to 54 ems and they all have malrotation of the bowel. Neuronal 
intestinal dysplasia was reported in only two patients (from one family) with a 
more complex mutation, presumably an inversion.2• 21 
Mutations in FLNA cause X-linked CSBS 
In a family with X-linked CSBS and in one isolated patient with CSBS, a two-base­
pair (bp) deletion in filamin A (FLNA) (c.16-17delCT) has been identified.3 More 
patients have been described with loss-of-function mutations in FLNA. Some of 
them had CSBS as part of the disease phenotype. In one male patient of an 
X-linked family described with Chronic Idiopathic Intestinal Pseudo-obstruction, 
another 2-bp deletion in the second exon of FLNA (c.65-66delAC) was found . 
• • 
This patient was diagnosed with malrotation, pyloric hypertrophy, intestinal 
pseudo-obstruction, and Congenital Short Bowel Syndrome.34 •35 Another male 
patient, stillborn at 33 weeks' gestation, was described with a duplication of 
the first 28 exons of FLNA. Prenatal ultrasounds showed normal growth with a 
single umbilical artery, umbilical vein varix, and persistent dilatation of the bowel, 
first seen at 20 weeks gestation. These findings were confirmed by an autopsy 
of the foetus, which also detected a bif id uvula, an atrial septa I defect, and a 
malrotated short small intestine of 45 ems (at this gestation stage around 164 
ems would be normal). The duplication was also detected in his mother, who was 
diagnosed with a bif id uvula and patent ductus arteriosus, and in his uncle, who 
had multiple congenital anomalies including a bifid uvula, intestinal malrotation, 
undescended testes, partial agenesis of the corpus callosum, patent ductus 
arteriosus, patent foramen ovale, ventricular septal defect and periventricular 
heterotopia, and in whom the small intestine measured only 115 ems at the age 
of 1 O years.36 Another patient with a hemizygous nonsense mutation in FLNA 
(c.7021 C> T, Q2341X) was diagnosed prenatally with a left diaphragmatic defect, 
which turned out to cause a displacement of the spleen, left hepatic lobe, and 
portions of the stomach and small intestine into the left hemithorax. He also 
had dysmorphic facial features, spina bifida occulta, natal tooth, periventricular 
heterotopia, a posterior fossa arachnoid cyst, and proximally placed thumbs. He 
died at 6 years of age and at autopsy his small intestine measured 68 cms.36 
Thus, CSBS patients with mutations in FLNA in general have multiple 
congenital anomalies and not only a congenital shortened small intestine. 
However, a mutation in the second exon of FLNA was identified in all reported 
male patients with X-linked CSBS but without other major congenital anomalies.3•35 
Screening of exon 2 of FLNA is therefore recommended in such cases. In 
X-linked families with CSBS patients with multiple congenital anomalies, it is 
worth screening the entire FLNA gene for mutations. 
The measured length of the small intestine of patients with mutations 
in the second exon of FLNA is 55 ems to 235 ems, and the age of diagnosis 
ranges from 1 day up till 15 years,4·14 •1 7  suggesting that, in some cases, the 
small intestine is less reduced in length and the diagnosis is made later in life 
compared to CSBS patients with mutations in CLMP. 
Table Overview of the reported CSBS patients. 
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Phenotypic diversity of FLNA mutations 
Mutations in FLNA are associated with a wide spectrum of disorders. Loss-of­
function mutations are found in patients with bilateral periventricular nodular 
heterotopia, a neuronal migration disorder characterized by seizures affecting 
mainly females since it is often lethal in males. Mutations that alternate the 
function of FLNA are associated with the following disorders: otopalatodigital 
syndromes types 1 and 2, frontometaphyseal dysplasia, and Melnick Needles 
syndrome. These syndromes constitute a phenotypic spectrum, including skeletal 
dysplasia, craniofacial-, cardiac-, genito-urinary and intestinal anomalies, and 
central nervous system defects.37 In addition, missense mutations in FLNA are 
associated with X-linked cardiac valvular dystrophy.38•39 
FLNA is a cytoskeletal protein that binds to actin and plays an important 
role in cell signalling and migration in response to environmental changes.37 FLNA 
has a well-characterized role in the cytoplasm, where it regulates cell shape by 
cross-linking actin filaments. In addition to this, a role for FLNA has recently 
been discovered in the nucleoli, where it inhibits ribosomal RNA transcription.40 
Histological findings in CSBS patients 
Based on the literature the question is whether CSBS is a finding in Chronic 
Idiopathic Intestinal Pseudo-obstruction patients or whether abnormal 
peristalsis is part of the features seen in CSBS patients.3·33·4 1  Although in 
most CSBS patients, the bowel wall seems macroscopically normal, Tanner 
et a/13 described an abnormal histology of the bowel wall revealed by silver 
staining in their patients. They found too many neurons in the ganglia and 
suggested that the normal fall-out of ganglion cells around the time of birth did 
not occur in CSBS patients. The neuronal nuclei showed clumped chromatin, 
which is characteristic for neuroblasts. They observed the intrinsic argyrophilic 
ganglion cells to be absent or much reduced in number: They argued that these 
histological findings may cause the motility abnormalities described in some 
cases.15 In addition, Schalamon et al observed an abnormal bowel wall with 
signs of neuronal intestinal dysplasia in one of their CSBS patients, who turned 
out to have a complex mutation in CLMP.1 The sister of this patient, who had the 
same homozygous mutation, was also born with a shortened small intestine and 
intestinal neuronal dysplasia.2 However, in other cases, no abnormalities of the 
• •  
nerves plexus were seen on routine or acetyl cholinesterase staining.1 •6•12• 16· 26• 
42 .
43 In one CSBS patient heterotopic gastric mucosa was found.4 1  Unfortunately, 
histology specimens were not obtained in all cases. 
Normal development of the small intestine 
To understand what might go wrong in the development of the small intestine 
in CSBS patients we have to know what happens during normal small intestinal 
development. What we do know is that the primitive gut tube is divided in the 
foregut, the midgut and the hindgut, and that all have their own arterial supply 
(the celiac artery, the superior mesenteric artery and the inferior mesenteric 
artery). The small intestine Gejunum and ileum) originates from the midgut, as 
do the distal duodenum, cecum, ascending colon, and the proximal two-thirds 
of the transverse colon. In the 5th week of embryonic life the future ileum is 
elongating rapidly (see Figure). As the abdominal cavity itself growths less 
rapidly, the midgut will form an anteroposterior loop, which is called the primary 
intestinal loop. The cranial limb of this loop includes the ileum and the caudal 
limb includes the ascending and transverse colons. In a 6 weeks old embryo the 
primary intestinal loop will herniate into the umbilicus forced by the elongation of 
the loop and the growth of other abdominal organs. At this time the loop rotates 
90 degrees counter clockwise around the axis of the superior mesenteric artery. 
The future ileum is now lying on the right and the cecum on the left. The cecum 
and the appendix continue to differentiate and the small intestine elongates 
further forming jejunal-ileal loops. During the 10th week of gestation, the intestinal 
loop returns rapidly to the abdominal cavity. It is not known what causes this 
retraction, but an increase in the size of the abdominal cavity and a relatively 
decrease in the size of the liver and kidneys seem to play an important role. 
The small intestine returns first and the ascending and transverse colons follow 
later. To reach the definitive configuration of the small and large intestines, the 
intestinal loop rotates another 180 degrees counter-clockwise.44•46 
Disease aetiology 
Before the identification of mutations in CLMP and FLNA explaining CSBS, 
various authors had proposed different hypotheses for CSBS pathogenesis. We 
will discuss these hypotheses based on distinguishing them into embryology and 
II 
intrauterine events, and the lack of neurotransmitters and hormones. 
Embryology and intrauterine events. Hamilton et a/1 suggested that the abnormally 
short small intestine originates during early embryologic development between 
the 7th and 10th week. They hypothesised that the accommodation of the primitive 
digestive tube in the intraumbilical coelom is prevented in CSBS patients. This 
would cause the primitive bowel to stay in the abdominal cavity so that the 
cranial portion of the bowel cannot elongate.1 But Aviram et aP5 observed the 
presence of bowel loops inside the umbilical cord on prenatal sonography in 
a patient with CSBS. The return of the intestine into the abdominal cavity was 
in fact delayed. Aviram et al speculated that incomplete dextral rotation and 
elongation of the bowel cause this delay, explaining the observed malrotation in 
CSBS patients.25 Delayed return of the intestine into the abdominal cavity is also 
associated with volvulus and intestinal obstruction.47 It has been speculated that 
intrauterine volvulus leading to ischemia prevents normal growth of the primitive 
bowel. In addition, antenatal intussusception followed by autoanastomosis and 
auto-amputation is suggested as a cause of CSBS.12 However, growth failure 
can also be the cause, rather than the outcome of the observed malrotation in 
CSBS patients.17 
Another hypothesis is that vascular events underlie CSBS.1 7 Intrauterine 
infarction of the bowel may lead to reabsorption of the ischemic bowel and 
result in a decreased length of the remaining gut. 
In cases in which autoanastomoses were found, intrauterine events like 
volvulus and infarction can be a reasonable explanation for the shortened small 
intestine.5 However, volvulus has been described in only three cases of CSBS. 
In addition, adhesions, atresia, stenosis and scars are rarely found in CSBS 
patients. These findings make intrauterine events less likely. In a case report 
of a premature neonate in whom the small bowel was absent, there was also 
no evidence on prenatal sonography of an abdominal wall defect or other intra­
abdominal anomalies.48 
Lack of neurotransmitters and hormones. As abnormal peristalsis has 
been observed in some CSBS patients, Sansaricq et al hypothesised that CSBS 
patients may lack synthesis of neurotransmitters.16 However, abnormal peristalsis 
is not reported in all patients. In addition, Schalamon et al suggested that CSBS 
patients lack growth-stimulating hormones like epidermal growth factor, insulin-
like growth factor, and human growth hormone, although they did not observe 
abnormal hormone levels in their patient.21 
Link between CLMP and FLNA 
We now know that mutations in CLMP and FLNA underlie CSBS pathology.2•3 
But it is not yet known whether CLMP and FLNA interact and, therefore, whether 
mutations in either CLMP or FLNA result in a similar course of events during the 
development of the small intestine. As CSBS patients with mutations in CLMP 
seem to have only a shortened small intestine and malrotation, the phenotype 
in these patients seems to be more restricted to the intestine, whereas patients 
with mutations in FLNA are more likely to have multiple congenital anomalies. 
However, CSBS patients with a deletion in the second exon of FLNA are very 
similar to patients with mutations in CLMP. This suggests that FLNA and CLMP 
are involved in the same protein network that is essential for normal short bowel 
development. 
FLNA is an actin-binding protein and its actin-binding domain is located 
in its N-terminal region.37.49 •50 Gargiulo et al showed abnormal actin organisation 
in the lymphoblastoid cell line of their patient in whom they found a c.65-
66delAC deletion in FLNA.35 There is therefore evidence that the cytoskeletal 
actin organisation is disturbed in CSBS patients with mutations in FLNA. 
Whether patients with mutations in CLMP have a similar problem is not known. 
Raschperger et a/showed, however, that CLMP co-localizes with actin filaments.31 
They speculated that CLMP interacts with a protein that directly binds to actin 
filaments, which would bring CLMP to the tight junction by anchoring CLMP in 
the actin cytoskeleton. They suggested that Z0-1 could be such an interacting 
protein. As FLNA also binds to actin filaments, we can speculate that FLNA is the 
l ink between CLMP and the actin cytoskeleton. It is known that FLNA interacts 
with other trans-membrane proteins like integrin beta and the cystic fibrosis 
trans-membrane conductance regulator (CFTR).50·51 There is also supportive 
evidence that FLNA plays a role in anchoring trans-membrane proteins in the 
cell membrane. It has been shown, for example, that for the expression of 
CFTR on the cell membrane, the interaction of CFTR with FLNA is important.51 
Furthermore, FLNA controls the internalization of the chemokine receptor 2B 
in different dynamic membrane structures.52 Therefore, we might suspect that 
• 
FLNA plays a role in the internalization of CLMP in the plasma membrane as 
well. It can be speculated that the mutations in FLNA influence the expression 
of CLMP on the plasma membrane. Further research is needed to determine 
whether CLMP and FLNA do indeed interact in the same protein network and, 
if so, which other proteins are involved in this network. We cannot exclude that 
different pathways underlie X-linked CSBS and autosomal recessive CSBS, with 
different disease mechanisms leading to a similar disease phenotype. 
It is not known whether there are more genes involved in the pathogenesis 
of CSBS than CLMP and FLNA. We did not identify a mutation in all the patients 
we screened for CLMP and the second exon of FLNA. However, we did not 
screen all the exons of FLNA in all the patients, and therefore this gene might 
still play a role in the disease development in some of the remaining patients. 
Based on the finding of an abnormal karyotype with a ring chromosome 4 in one 
CSBS patient with multiple congenital anomalies,30 a gene on the long arm of 
chromosome 4 might be involved as well. In addition, the balanced translocation 
found in the patient reported by De Backer et aP2 might have led to undetected 
microdeletions. Therefore, additional genes on chromosomes 2 and 11 might 
well play a role. Research on the protein networks of CLMP and FLNA might help 
to find more candidate genes. 
Link between CLMP and FLNA and the proposed hypotheses 
How mutations in CLMP and FLNA lead to Congenital Short Bowel syndrome 
remains obscure and whether we can link these genes with the proposed 
hypotheses is hard to tell. As the affected genes in CSBS patients do not encode 
for neurotransmitters, and as far as we know do not have a link to the production 
of neurotransmitters, it is very unlikely that a lack of neurotransmitters, as 
proposed by Sansaricq et a/,16 is the explanation of the shortened small intestine. 
FLNA is however important in vascular development. Two different mouse 
models for FLNA showed vascular defects53·54 and developmental anomalies in 
the blood vessels have also been reported in patients with FLNA mutations.55·56 
An intrauterine vascular event causing small intestinal infarction, as proposed 
by Kern et a/,17 might therefore be a reasonable explanation. The observation 
of omphalocoele in patients with FLNA mutations37 supports Hamilton et afs 
hypothesis1 that the developmental defect in CSBS patients originates in the 
I 
embryonic stage at which the bowel is accommodated in the intraumbilical 
coelom. Furthermore, Aviram et al25 observed a delayed return of the bowel into 
the abdominal cavity in a patient with CSBS. A similar finding was observed in 
one of the mouse models for FLNA, in which there was a delayed resorption of 
the umbilical hernia.54 More research is needed to understand the embryological 
events leading to the CSBS phenotype and CLMP-null mice might help further 
our understanding of the disease pathology. 
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Abstract 
Megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS) is a rare 
autosomal recessive disorder affecting the bladder and the intestine. So far, 
no gene has been identified for this disease although knockout studies in 
mice have implicated the human orthologues of the a3 subunit (CHRNA3) and 
the �4 subunit ( CHRNB4) of the nicotinic acetylcholine receptor as candidate 
genes. We performed homozygosity mapping and exome sequencing in one 
consanguineous family with one affected girl using 300K SNP arrays. We 
identified three homozygous regions on chromosomes 1, 2 and 8, respectively. 
However, no pathogenic mutation was identified in these regions. Neither were 
the candidate genes CHRNA3 and CHRNB4 located in these regions. Repeating 
the analysis with a higher resolution array in which the probes are more evenly 
distributed and with a more efficient exome capturing and enrichment kit, and 
including more patients in our study, might help to find the gene underlying MMIHS . 
• 
Introduction 
Megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS) is a rare 
congenital disorder characterized by abdominal distension due to a much 
dilated non-obstructed bladder, microcolon and decreased or absent intestinal 
peristalsis.1 Since the first report of this condition by Berdan et al in 1976 ,1 more 
than 200 cases have been described in literature. MMIHS is more common in 
girls ,  with a female to male ratio of 2.4:1.2 MMIHS patients often die before 
the age of 6 months due to the complications of the total parenteral nutrition 
that they require because of the intestinal hypoperistalsis.3 The complications 
include sepsis. It is believed that the condition has a genetic aetiology since 18 
families have been reported with two affected siblings and one family with three 
affected siblings.2•4 In four families the parents were consanguineous, suggesting 
an autosomal recessive pattern of inheritance.2 .4 So far, no genetic cause of the 
human disease has been identified, although knockout studies in mice have 
implicated some candidate genes. Knockout mice for the nicotinic acetylcholine 
receptor subunits, a3-/- and 132-/-,134-/-, all have an enlarged bladder,5•6 and 
intestinal hypoperistalsis was present in the 132-/-, 134-/- mice. Only the double 
knockout of both 132 and 134 subunits resulted in the phenotype and lack of only 
134 gave deficiency of bladder contractions, but no megacystis. The intestinal 
length was also reduced in the 132-/-,134-/- mice, but because the mice were 
also  smaller in size it was proportionally reduced.6 Lack of the a3 subunit was 
observed in MMIHS tissues, and therefore mutations in the human orthologues 
of the a3 subunit ( CHRNA3) and the 134 subunit ( CHRNB4) have been suggested 
to cause MMIHS.7 
Our aim was to identify the gene for MMIHS. We therefore performed 
homozygosity mapping followed by exome-sequencing. In analyzing the data 
we focused on genes in the homozygous regions. We also checked whether the 
proposed candidate genes, the human orthologues of the a3 subunit (CHRNA3) 
and the 134 subunit ( CHRNB4) of the nicotinic acetylcholine receptor, were 




The MMIHS patient included in this study was prenatally diagnosed with MMIHS. 
Ultrasound at 20 weeks' gestation revealed a megabladder. Labour was induced 
at 34+4 weeks for polyhydramnion and a female infant of 3000 gm (+2.5 SD) 
was born with APGAR scores of 9/10. The diagnosis of MMIHS was confirmed by 
ultrasound of the abdomen and by double-contrast barium enema. Radiography 
was also suggestive for malrotation. The stomach and bladder were atonic. The 
patient died a few days after birth due to infection and apnea's. The Caucasian 
parents were distantly related (over five generations). The study protocol was 
approved by the institutional and national ethics review committees at the 
University Medical Centre Groningen (NL35920.042.11  ), and informed consent 
was obtained. 
Homozygosity mapping 
Genomic DNA of the patient and the parents was extracted from peripheral 
lymphocytes by standard methods. A genome-wide scan was performed on the 
patient using the lllumina 300K SNP array (HumanCytoSNP-12.v2 DNA Analysis 
BeadChip) according to the manufacturer's instructions (lllumina, San Diego, CA). 
Homozygosity mapping was performed by an automatic search for a minimum of 
15 consecutive homozygous probes and a region of minimum 2 Mb. 
Exome sequencing 
Five µg of the patient's DNA was used for exome sequencing. Exome capturing 
and enrichment was performed as per manufacturer's instructions (hybrid capture 
SureSelect Human All Exon kit (38 Mb), Agilent Technologies, Amsterdam, the 
Netherlands). This method targets most human exons (the region it targets is 
around 38 Mb). The captured fragments were subsequently sequenced on the 
Genome Analyzer II (lllumina, San Diego, USA). The alignment to the human 
genome sequences GRCh37 /hg19, the SNP calling, and the insertion-deletion 
calling were performed for only the three homozygous regions using CLC 
genomics workbench (CLC Bio). We set the threshold criteria for the homozygous 
SNP and insertion-deletion calling at the ratio 20:80 for 'ReferencesNariant' and 
: . 
Table 1. Primer sequences for confirmation of variants by Sanger sequencing 
Primer sequences, 5'7 3' 
Gene Forward 









PCR cond1t1ons: 35 cycles of denaturat1on at 95°C for 1 minute, annealing at 60°C for 1 minute and polymerization 
at 72°C for 1 minute. 
the coverage at more than 1 O times. The variants that passed these criteria 
but which were present in dbSNP v.1.31  or in the "in-house controls" variants 
database, were excluded. This variants database contained all the variants 
that were present in unrelated samples that were run at the same time on the 
Genome Analyzer II (lllumina). When newer versions of dbSNP became available 
we rechecked for the presence of the variants in these databases. 
Sanger sequencing 
Confirmation of the candidate SNPs was performed by Sanger sequencing in 
both the patient and the parents. For PCR conditions and primer sequences 
see Table 1. Sequencing was performed (forward and reverse) with dye-labelled 
primers (Big Dye Terminator v3.1 Sequencing Kit, Applied Biosystems, Foster 
City, CA) on an ABI 3730 automated sequencer (Applied Biosystems) 
In Si/ico Analysis of the missense mutation 
The effect of the missense mutation was evaluated by the 'Russell method' at 
the European Molecular Biology Laboratory (available from: http://www.russelllab. 
org/aas/)8 and by the polymorphism phenotyping algorithm (PolyPhen-2) (http:// 
genetics.bwh.harvard.edu/pph/). 
RT-PCR 
Because the bowel is affected in MMIHS, we determined the expression of the 
orthologues of the candidate genes in which the candidate variants were found 
in mouse intestine. Total RNA was isolated from mice gut embryonic day 14.5 
according to the manufacturer's instructions (Qiagen, Venlo, the Netherlands). A 
total of 0.5 µg of total RNA was used as a template to synthesize complementary 
DNA (cDNA) according to the manufacturer's instructions (Fermentas, Utrecht, 
the Netherlands). PCR conditions and primer sequences are given in Table 2. 
One µL of cDNA was used for the PCR in a total volume of 30 µL. PCR products 
were checked by gel electrophoresis. 
Results 
Homozygosity mapping was applied using an lllumina 300K SNP array on the 
DNA of the MMIHS patient. Three homozygous regions were identified on 
chromosome 1 (1q31.2-32.2), chromosome 2 (2q11.1-14.1) and chromosome 8 
(8p23.3-23), comprising about 15, 19 and 6 MB, respectively. 
A total of 3 GB of single-end sequence data was generated for the 
patient, with a mean read length of 79 bps. More than 93.5% of the bases were 
mapped to the target exons and, on average, 84.6% of the exome was covered 
at least ten times. The list of all the candidate variants in the homozygous 
regions, the summary of the CLC-Bio analysis, and the statistics of the exome 
sequencing, are presented in Tables 3, 4 and 5, respectively. Only three of the 
variants in the homozygous regions were located in coding sequences. All these 
variants resulted in amino acid changes (missense variants), and were located 
in the genes MYOG, A TP284 and IL24. 
Validation of all candidate variants with Sanger sequencing confirmed 
Table 2. Primer sequences for RT-PCR. 

















PCR conditions: 35 cycles of denaturation at 95°C for 1 minute, annealing at 58,5"C for 1 minute and polymerization at 72°C 
for 1 minute. 
Table 3. Variants identified in the homozygous regions 
No Chromosome Position Reference Alternative Coverage Gene name Function Amino acid change 
1 1 200974176 G A 32 KIF21B lntron 
2 1 201077321 C A 11 CI\CNA1S ln1ron 
3 1 203053787 C T 17 MYOG Mosaanse Ala181TIY 
4 1 203696548 C T 109 ATP28<1 - Ser1053Phe 
5 1 203802214 T G 10 ZC3H11A lntron 
6 1 205388149 C T 15 LEMD1 lntron 
7 1 207075619 A C 10 IL24 lntron 
8 1 207076321 T G 18 IL24 Mossense Leu22Val, Leu180Val 
9 1 207078220 T C 38 FAIM3 utr-3 
10 2 95426753 T C 10 AN<AD20B lnttlfgen,c 
1 1  2 95475073 A G 10 AN<AD20B lnlergemc 
1 2  2 95599053 C G 10 LOC442028 lnte,gemc 
1 3  2 96940649 T C 20 SNRNP200 utr-3 
14 2 100181826 G A 89 AFF3 lntron 
15 2 102000169 C T 57 CAEG2 lntron 
16 2 102378792 A C 11 MAP4K4 lntron 
17 2 102773101 G A 10 IL1R1 ln1ron 
1 8  2 107050624 G A 65 AGPD3 ln1ron 
1 9  2 109311211 C T 13 LOC100288532 lntergen1c 
20 2 109311212 T C 13 LOC100288532 lntergen1c 
21 2 109311333 T C 24 LOC100288532 lntergen1c 
22 2 112141781 T G 38 PAFAH1P2 lntergemc 
23 2 112142170 G C 98 PAFAH1P2 lnteraenic 
24 2 112544067 G A 11 ANAPC1 lntron 
25 2 1 13077182 C T 11 ZC3H6 lntron 
26 2 1 13077183 A G 11 ZC3H6 lntron 
27 8 1719112 C T 31 CLN8 u1r-5 
that the patient was homozygous and the parents were heterozygous for these 
variants (see Figure 1). As the bowel is affected in MMIHS, we determined the 
expression of the mouse orthologues of MYOG, ATP2B4 and IL24 in the gut 
of a 14.5-day old mouse embryo by RT -PCR. ATP2B4 is expressed during the 
development of the mouse gut (see Figure 2), but we were not able to determine 
MYOG and /L24 expression. For all three missense variants we also determined 
their predicted effect using the Russell and Polyphen prediction programs. 
Only the missense variant in ATP2B4 was predicted to be pathogenic by both 
Polyphen and Russell. The missense variant in ATP2B4 is therefore a plausible 
candidate. However, after we had done all the confirmation and functional work, 
we rechecked the latest release of dbSNP (v.1.34) and the variant was reported 
to be present in the normal population and can therefore no longer be considered 
as a candidate. 
The MMIHS candidate genes CHRNA3 and CHRNB4 are located on chromosome 
15q24 and not in a homozygous region. 
g to unravel the genetics of 
Table 4. Summary of analysis in CLC-Bio. 
Variants Number 
Identified by CLC-Bio 1572 
In homozygous regions 297 
Not identified in dbSNP131 and 1000 
27 
Genomes 
Chromosome 1 9 
Chromosome 2 17 
Chromosome B 1 
Table 5. Summary of statistics of exome sequencing. 
Bait territory 38925539 
Mean bait overage 36,757176 
Mean target coverage 38,071198 
Targets covered � 2x 93,50% 
Targets covered � lOx 84,60% 
Targets covered � 20x 71,40% 
Targets covered � 30x 55,90% 
Discussion 
Here, we describe an attempt to identify the gene underlying MMIHS in one 
female patient of a consanguineous familiy by homozygosity mapping and 
exome sequencing. We identified three candidate loci by homozygosity mapping 
using 300K SNP arrays and after excluding the variants known in dbSNP v.1.31, 
we identified three candidate variants all residing in the homozygous region on 
chromosome 1. These variants were all missense variants leading to an amino 
acid substitution. Only the variant in A TP284 was predicted to be pathogenic 
and because the variant was absent in dbSNP v.1.31, we determined the 
expression of ATP284 during the development of the intestine in mice. ATP2B4 
is a plasma membrane pump Ca(2+)-ATPase. It is expressed in skeletal muscle, 
small intestine, heart, spinal cord, and brain.9 In MMIHS the peristalsis of the 
small intestine is affected, so this gene seemed to be a good candidate gene 
for MMIHS. However, on checking a more recent version of dbSNP (v1 .34), the 
variant proved to be present in the normal population. Although the variant is 
present in a heterozygous state in the population, the allele frequency is 1.1 % . 
• 
Thus, it is very unlikely that this variant is the cause of MMIHS. There are only 
around 200 MMIHS patients reported in the literature and the frequency of 
mutations causing MMIHS is expected to be very low in the population. 
As the a3-/- and �2-/-,�4-/- mice show very similar features to MMIHS5•6 
and lack of the a3 subunit was seen in MMIHS tissues,7 the human orthologues 
of the a3 subunit (CHRNA3) and the �4 subunit (CHRNB4) of the nicotinic 
acetylcholine receptor are good candidate genes for MMIHS. T hese genes 
were, however, not located in the homozygous regions. Lev-Lehman et al. also 
screened CHRNA3 and CHRNB4 in 1 3  MMIHS families, including seven MMIHS 
patients, and did not find any loss-of-function mutations.10 
To conclude, although we sequenced all the genes in this patient, we 
were not able to find the disease causing mutation. It is possible that we missed 
the mutation due to a lack of coverage of the exome. We set the criteria on 
coverage at more than ten times, which meant that the gene coverage of the 
target sequences was only 84.6% and 1 5.4 % of the variants present in these 
sequences were missed. Furthermore, the enrichment kit used in this experiment 
covered only 81 .33% of the exome, meaning that we had already missed about 
1 9% of the exomic data. We conclude that we missed about 31  % of the total 
exomic data and thus may well have missed the mutation. 
Another possibility is that we missed the homozygous region. A higher 
resolution SNP array in which the probes are more evenly distributed might 
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Figure 1. Validation of variants by Sanger sequencing in patient and parents 





Figure 2. Expression of the orthologues of MYOG, ATP284 and /L24 in the intestine of the 
mouse at embryonic day 1 4.5. 
help to pick up smaller homozygous regions, which are missed by using the 
300K SNP array. These might contain the disease causing mutations. A higher 
resolution SNP array might also help to narrow down the homozygous regions 
we have identified so far. 
In order to find the disease causing mutation we will repeat both the 
SNP array as well as the exome sequencing. We will use a higher density SNP 
array in which the probes are more or less evenly distributed over the genome, 
the human Omniexpress 700K array (lllumina). In addition we will use the 51  MB 
Human All Exons V4 SureSelect enrichment kit (Agilent), that will cover more 
of the exome. We recently used this kit and acquired 97.5% coverage of the 
targeted regions, with a coverage of at least 10  reads. We will also include 
more patients in the next study. All this 
will, we hope, help us to identify the 
disease causing mutation. 
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G eneral discus sion and 
future p ers p ectiv e s  
CLMP in recessive Congenital Short Bowel Syndrome 
Congenital Short Bowel Syndrome is characterized by a shortened small intestine 
and malrotation. When the disease is inherited in an autosomal recessive pattern, 
it is caused by loss-of-function mutations in CLMP (coxsackie- and adenovirus 
receptor-like membrane protein}.1 CLMP is a trans-membrane protein that co­
localizes with the tight junction proteins Z0-11 -3 and occludin.2 The hypothesis 
of a possible link between CLMP and Z0-1 was further supported by the 
observation of an increased cytoplasmatic pool of Z0-1 when we transfected 
a mutant-CLMP (encoded by CLMP containing the missense mutation V124D 
that we identified in one of the CSBS patients), that itself also mislocalized 
to the cytoplasm, in CHO and T84 cells.1 lmmunostaining on human embryos 
showed that CLMP is expressed in the intestine during different stages of human 
development. Knock down of the orthologue of CLMP in zebrafish resulted in 
general developmental defects and absence of the goblet cells in the intestine, 
suggesting that the small intestine was absent.1 However, the function of CLMP 
is still largely unclear. 
Elucidating the function of CLMP 
Because CLMP co-localizes with tight junction proteins, and as tight junction 
proteins like Z0-1 play a role in proliferation,4•5 we suggested that loss-of­
function of CLMP could affect proliferation of small intestinal cells during human 
development and thereby causes a shortened small intestine.1 To investigate this 
hypothesis, we overexpressed CLMP in T84 cells. We observed that CLMP did 
not affect the proliferation of these cells (Chapter 3); neither did overexpression 
of CLMP influence migration, cell viability or transepithelial electrical resistance 
(Chapter 3). Although it has been shown that CLMP acts as an adhesion 
molecule,2•6 it does not have a strong adhesion capability (Chapter 3). So the 
function of CLMP remains unclear and we do not know why loss-of-function 
mutations lead to Congenital Short Bowel Syndrome. An alternative hypothesis is 
that CLMP plays a role in the differentiation of the progenitors of small intestinal 
cells. This hypothesis is based on the observation that CAR (coxsackie- and 
adenovirus receptor), the closest homologue to CLMP with 31% identity on the 
protein level, has a possible role in the intercellular communication between 
stromal ependymal cells and neuronal stem cells suggested by Hauwel et a/.7 It 
has been shown that neurospheres, a culture system composed of free-floating 
clusters of neural stem cells, plated on a CAR-coated petridish adhere strongly 
and rapidly, inducing a shift in the mixed population of proliferating cells. CAR 
signalling promotes the cells' spreading and primes them for the production 
of neurons. This might imply a role for CAR in the differentiation of neuronal 
stem cells into neurons.7 Knowing this, and knowing that loss-of-function of 
CLMP results in a congenital short small intestine, it would be interesting to 
determine whether CLMP plays a role in stem cells. Recently, intestinal stem cell 
cultures have been established.8 Because these stem cell cultures resemble 
the small intestine in such a way that they have the same architecture, cell 
type composition, and self-renewal ability as the small intestine, they are called 
human small intestinal organoids.8 These small intestinal organoids, presuming 
they express CLMP, would provide an excellent model system to study the 
function of CLMP. For long-term human intestinal stem cell culture, nicotinamide, 
A83-01 (Alk4/5/7 inhibitor) and SB202190 (p38 inhibitor) are needed. Adding 
nicotinamide prolongs the cell culture from 7 days to 1 month. With A83-02 and 
SB202190, the human intestinal organoids could be expanded for at least 6 
months. However, there are no differentiated cells present in these long-term 
human intestinal stem cell cultures. For differentiation, withdrawal of wnt is 
required, which, interestingly does not result in the production of goblet cells. 
For the production of goblet cells in these cultures, nicotinamide and SB202190 
have to be withdrawn as well.8 Knockdown of the orthologue of CLMP in zebra fish 
resulted in the absence of goblet cells,1 indicating that CLMP might well play a 
role in differentiation. It will therefore be interesting to determine whether CLMP 
is downregulated in human intestinal organoids treated with nicotinamide and 
SB202190, as these cultures do not produce goblet cells and are thus similar to 
CLMP knockdown zebrafish. 
The availability of an endogenously CLMP expressing cell line might help 
to elucidate the function of CLMP. We have searched for such a cell line, but have 
so far been unable to find a cell line that does express CLMP (unpublished data). 
However, according to the protein atlas, there should be a few cell lines that might 
be worth checking, for instance, according to this atlas, CLMP should be strongly 
expressed in Hep-G2 cells (http://www.proteinatlas.org/ENSG00000166250/ 
cell). Screening these cell lines for endogenous expression of CLMP will be the 
first step. If a cell line is found that does indeed endogenously express CLMP, 
knock-down experiments can be performed to determine the effects on the 
same cellular processes we studied in the T84 CLMP overexpressing cell lines. 
Besides looking for specific functions, like migration and proliferation, in these cell 
lines endogenously expressing CLMP, looking for proteins that physically interact 
with CLMP would be a less biased approach to studying the function of CLMP. 
This can be done, for instance, by pull-down experiments and subsequent mass 
spectrometry, thereby identifying functional interactors of CLMP. For this, the cell 
lines endogenously expressing CLMP will be crucial. Finding the interactors of 
CLMP would be of great help in elucidating the function of CLMP as the function 
will be known for some, if not most, of the interactors. A similar assay that could 
be performed is a yeast two-hybrid assay; an assay that can be performed even 
if no cell line can be identified that endogenously expresses CLMP. A protein 
network can be built and would help to gain insight into the role of CLMP in 
different processes. As CLMP is a membrane protein, its hydrophobic character 
makes it difficult to study its interactors using a conventional yeast two-hybrid 
assay, which requires an interaction between proteins in the nucleus; therefore 
interactions of only the soluble domains of membrane proteins are possible in a 
conventional yeast two-hybrid assay. A modified assay, a membrane yeast two­
hybrid assay, has been designed for studying membrane proteins.9 In this system 
the split ubiquitin principle is used as a sensor of protein-protein interactions. 
This assay, therefore, does not require an interaction between proteins in the 
nucleus; it only requires that the membrane protein to be studied, in our case 
CLMP, has its N and/or C terminus located in the cytosol. This is the case for 
CLMP, which makes the assay suitable to use in identifying the interactors of 
CLMP. 
In addition to in vitro models for studying the function of CLMP, in vivo 
models might also be helpful. As described in Chapter 2, we developed a zebra fish 
model for Congenital Short Bowel Syndrome.1 However, the development 
of the intestine in zebrafish is quite different from that in humans. Since the 
development of the intestine in mice is more similar to that in humans, a CLMP 
knockout mouse model might help us to better understand the disease aetiology 
in Congenital Short Bowel Syndrome patients. 
• 
FLNA in X-linked Congenital Short Bowel Syndrome 
Male patients with mutations in FLNA can also present with Congenital Short 
Bowel Syndrome. A two-base-pair deletion was identified in an X-linked CSBS 
family and in an isolated male patient with a de novo mutation (Chapter 4). The 
mutation is located in between the first two methionines of FLNA, and the start 
of translation of FLNA can occur from both methionines, so that the mutation 
probably only affects the long isoform of FLNA. This could well explain why such 
a severe mutation causes a rather mild phenotype. As the phenotype of CSBS 
patients with mutations in CLMP is very similar to those with a two-base-pair 
deletion in FLNA, there might be an interaction between CLMP and FLNA. 
Elucidating the role of FLNA in intestinal development 
FLNA is a cytoskeletal protein and mutations in FLNA are associated with a 
wide spectrum of disorders, including periventricular nodular heterotopia, 
otopalatodigital syndromes types 1 and 2, frontometaphyseal dysplasia, Melnick 
Needles syndrome, and X-linked cardiac valvular dystrophy.10-12 Our findings 
add Congenital Short Bowel Syndrome to the list as a possible presenting 
phenotype in male patients with a mutation in FLNA. We, therefore, emphasize 
the importance of FLNA in intestinal development. Gastrointestinal symptoms 
have been described in more patients with FLNA mutations. However, most of 
them presented with multiple congenital anomalies, of which a congenital short 
small intestine was only one of them.1 3  The patients we describe in Chapter 4, 
and the patient described by Gargiulo et al, all have a two-base-pair deletion 
in the second exon of FLNA between the first two methionines; their main 
presenting symptoms were gastrointestinal. However, the index patient of the 
family described by Gargiulo et al developed asymmetrical spastic diplegia 
and an abnormal intermediate signal in the peritrigonal white matter was seen 
on MRl.14 Thus, this patient did have central nervous system involvement. We 
cannot exclude central nervous system involvement in the patients we describe 
in Chapter 4 because no MRI brain scans were available. However, they did 
not have any clinical neurological abnormalities like seizures or spasticity. 
Furthermore, it is likely that the patients described in Chapter 4 do not have any 
central nervous system involvement, because not all patients with mutations 
in FLNA have central nervous system involvement. The mother of the proband 
described by Kapur et al did have a duplication of the first 28 exons of FLNA, 
but had a normal cranial MRl.13 We therefore argue that male patients who 
present with CSBS, with or without central nervous system involvement, must be 
screened for mutations between the first two methionines in the second exon of 
FLNA. Because it has been shown that translation of FLNA can occur from both 
the first or second methionine,14 the two-base-pair deletion in FLNA in the male 
CSBS patients will probably only affect the long form of FLNA. A slightly shorter 
protein, the short isoform of FLNA, can still be translated. We hypothesized 
that the first 27 amino acids, the ones lacking in this shorter FLNA protein, 
might be important for the development of the bowel, but less important for the 
development of the other organs like the heart. Thorough genotype-phenotype 
studies in patients with mutations in FLNA might help to further our understanding 
of the function(s) of the different domains of FLNA. 
Two mouse models for FLNA have been generated.15·16 Fina-null mice 
show maldeveloped bloodvessels and major cardiac defects.15 They also show 
delayed resorption of their umbilical hernia.16 However, the intestines of these 
mice have not been described. Therefore, it might be interesting to study the 
intestines of these mice macroscopically and microscopically. As discussed in 
the next section, FLNA and CLMP may interact, or be players in a common 
protein network, and it might therefore be interesting to determine whether CLMP 
staining in the intestine differs between the wild-type and the knockout mice. 
Link between CLMP and FLNA 
As the phenotypes of Congenital Short Bowel Syndrome patients with mutations 
in CLMP and of male CSBS patients with mutations in the second exon of FLNA 
are very similar (Chapter 4)1 it is likely that CLMP and FLNA interact or are 
players in a common protein network. Since FLNA is a cytoskeletal protein of 
280 kDa,10 overexpression studies with FLNA are difficult, if not impossible, 
to perform. As discussed above, the male patients with FLNA mutations who 
present with CSBS as the main phenotype have mutations between the first 
and second methionine (Chapter 4). We therefore hypothesized that the first 27 
amino acids, the ones between the first and second methionine, are important 
for the normal development of the small intestine. This part of FLNA might 
contain the domain that physically interacts with CLMP and overexpression of a 
protein consisting of the first 27 amino acids of FLNA could be used to perform 
pull-down experiments with CLMP to test our hypothesis. 
Co-immuno-staining of CLMP and FLNA in a representative cell line 
that expresses both proteins is a way to determine whether the localization 
of CLMP and FLNA overlap and whether an interaction between both proteins 
might therefore be likely. There is supporting evidence that FLNA plays a role 
in anchoring trans-membrane proteins in the cell membrane. We therefore 
hypothesized that FLNA might be important for a correct membrane localization 
of CLMP (Chapter 6) A knock-out cell line of FLNA, but positive for CLMP, could 
be useful to test this hypothesis. Expressing CLMP in a CLMP-negative cell line 
with and without FLNA could also help to determine whether FLNA is needed for 
the normal localization of CLMP at the cell membrane. 
It seems, however, likely that FLNA and CLMP do not have a direct 
interaction, but rather that they are indirectly linked. Searching for overlapping 
interactors will therefore help to build the protein network in which they both are 
involved. A yeast two-hybrid assay with FLNA will probably reveal many proteins 
that are not linked to CLMP. Therefore, using only the first 27 amino acids of FLNA 
for the yeast two-hybrid assay would increase the chance of finding common 
interactors of FLNA and CLMP. Pull-down techniques and mass spectrometry 
are again good alternatives to identify possible interactors. Indirect interactions 
of the orthologues of CLMP and FLNA can be studied in a zebrafish model.17 
More genes involved in Congenital Short Bowel Syndrome 
Because we did not find any mutation in CLMP and FLNA in two female CSBS 
patients, more genes might well be involved in the pathogenesis of Congenital 
Short Bowel Syndrome. One of these mutation-negative patients presented 
at the age of 12 weeks with failure to thrive and abdominal distension; she 
has already been described in the literature.18 At laparotomy, malrotation and 
congenital short bowel syndrome were found. The length of her small intestine 
was 80 ems (normal length approximately 245 ems). Around 45 ems of her 
small intestine was dilated and needed to be removed. Almost half of this tissue 
consisted of heterotopic fundic gastric mucosa.18 The other female patient 
described in Chapter 5 had not been described before. She presented with 
persistent pulmonary hypertension and at autopsy a congenital short small 
intestine with a length of 98 cm was found. 
Because we are now able to perform whole-exome sequencing of 
individuals, we could potentially identify the causative gene mutations in these 
individual patients. However, as these would be single-patient studies, additional 
functional assays will be needed to determine whether the identified mutations 
are really causative. 
Searching for genes involved in Megacystis-microcolon-lntestinal hypoperistalsis 
Syndrome 
Megacystis Microcolon Intestinal Hypoperistalsis Syndrome (MMIHS) is 
characterized by abdominal distension due to a largely dilated non-obstructed 
bladder, microcolon, and decreased or absent intestinal peristalsis.19 Malrotation 
and short bowel syndrome, the main features in Congenital Short Bowel 
Syndrome, have also been reported in MMIHS patients. Affected siblings of 
both sexes have been described in 19 MMIHS families, while the unaffected 
parents were consanguineous in four MMIHS families, suggesting an autosomal 
recessive pattern of inheritance.20•21 The genetic cause is, however, unknown. We 
performed 300K SNP arrays and homozygosity mapping in one consanguineous 
family. We identified three homozygous regions on chromosomes 1, 2 and 8, but 
so far we have not been able to identify the disease-causing mutation (Chapter 
7). 
For identifying the underlying gene in autosomal recessive disorders, 
one patient can be sufficient (see Chapter 2), however, to get more supportive 
evidence we need more patients to be included. More patients would be helpful 
to identify an overlapping homozygous region. A SNP array with a higher density 
could help to pick up homozygous regions we have missed, and help to narrow 
down the regions we found. In addition, an array in which the probes are more 
evenly distributed can also help to identify homozygous regions we have missed. 
We will therefore use the human Omniexpress 700K SNP array (lllumina), which is 
a higher density SNP array than the one we have used so far (300K); the probes 
. • 
on this larger array are also more evenly distributed. In addit i on, for exome 
sequencing we will use the 51 Mb Human All Exons V4 SureSelect enrichment 
kit (Agilent), which will cover more of the exome. We recently used this k it and 
gained 97.5% coverage of the targeted regions with a coverage of minimum 10 
reads, and we hope these data will enable us to identify the causative mutations 
in MMIHS patients. Depending on the gene(s) found to underlie MMIHS, additional 
functional assays will be performed. 
Implications of our f indings for genetic counselling and therapy 
In this thesis we describe the identification of loss-of-funct ion mutations in CLMP 
in autosomal recessive Congenital Short Bowel Syndrome and a two-base-pair 
deletion in FLNA in male CSBS patients. These findings suggest that when 
a patient presents with Congenital Short Bowel Syndrome, mutation analysis 
should be performed in CLMP and/or FLNA, depending on the full phenotype. In 
general, screening for mutations in CLMP should be the first step, especially if 
the parents are consanguineous. A male patient with a family history of a patent 
ductus arteri osus or epilepsy should be screened for mutations in FLNA. Finding 
a mutation greatly improves genetic counselling and makes prenatal diagnostic 
testing possible. 
Because CLMP is also expressed in the small intestine in adults,2 we 
hypothesised that CLMP has an important function in more than human embryonic 
development. We know that the intestine grows longer up to adulthood, because 
the length of the intestine in adults is 600 ems, on average, while at birth it is 
250 ems, on average. CLMP might have an important role in this elongat ion 
process or in the intestinal adaptation process after surgical resection. Studies 
have been performed to determine the effects of growth factors, such as growth 
hormone, keratinocyte growth factor, epidermal growth factor, and glucagon­
l ike peptide-2, on the intestinal adaptation process.22·25 Similar studies could 
be performed to see whether CLMP has an effect on intestinal adaptation and 
whether it can be used in some form of treatment for short bowel syndrome . 
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Summa r y  
The focus of this thesis is on two inherited congenital bowel syndromes for 
which the genes had not been identified at the time we started our study, namely 
Congenital Short Bowel Syndrome (CSBS) and Megacystis-microcolon-intestinal 
hypoperistalsis syndrome (MMIHS). In Chapter 1 we discuss the history, clinical 
presentation, histological findings, genetics and pathogenesis of both syndromes. 
In Chapter 2 we describe the identification of loss-of-function mutations 
in Coxsackie- and adenovirus receptor-Like Membrane Protein (CLMP) in 
Congenital Short Bowel Syndrome patients. Congenital Short Bowel Syndrome 
is characterized by a congenital short small intestine of 50 ems on average 
compared to a normal length of 250 ems at birth, and malrotation. CSBS was 
believed to be an autosomal recessive disease because it occurs in both males 
and females, it is mostly seen in siblings in one generation of a family, the parents 
are not affected, and in several cases the parents have proved to be distantly 
related (consanguineous families). We performed homozygosity mapping in 
five CSBS patients from four different families and identified an overlapping 
homozygous region in four of the five patients. A thorough examination of the 
array data led to the identification of not only a shared homozygous region, but 
also of a homozygous deletion concerning the second exon of CLMP in one of 
the patients. Screening the other patients for mutations in this gene revealed 
different loss-of-function mutations in CLMP. CLMP is a cell membrane protein 
that co-localizes with the tight-junction protein ZO-1. The hypothesis that CLMP 
interacts with ZO-1 was further supported by the observation of an increased 
cytoplasmatic pool of ZO-1 when we transfected a mutant-CLMP (encoded 
by CLMP containing the missense mutation V124D we identified in one of the 
CSBS patients), that itself also mislocalized to the cytoplasm, in CHO and T84 
cells. Furthermore, we showed that CLMP is expressed in the intestine of human 
embryos throughout development. Knock-down experiments in zebrafish resulted 
in general developmental defects, including shortening of the intestine and the 
absence of goblet cells. Goblet cells are characteristic for the mid-intestine in 
zebrafish, which resembles the small intestine in human beings, suggesting that 
the small intestine was absent in these morphant zebrafish. 
Thus, we identified loss-of-function mutations in CLMP in patients with 
Congenital Short Bowel Syndrome, suggesting a major role for CLMP in 
intestinal development. Although we know that CLMP co-localizes with tight 
junction proteins, the function of CLMP is not well understood. To determine the 
function of CLMP we performed functional assays in human intestinal epithelial 
T84 cells and in Chinese Hamster Ovary (CHO) cells; these are described in 
Chapter 3. We transduced both wild-type (WT)-CLMP and mutant-CLMP into 
T84 cells and determined the role of CLMP in migration, proliferation, viability 
and transepithelial electrical resistance. Our data show that expression of WT­
CLMP or mutant-CLMP does not affect any of these processes in the cell model 
we used. Moreover, our aggregation assays in a different cell line (CHO) showed 
that CLMP does not act as a strong adhesion molecule. Thus, our data suggest 
that, in the in vitro model systems we used, key processes involved in intestinal 
epithelial development appear to be unaffected by WT-CLMP as well as by 
mutant-CLMP. Further research is needed to determine the role of CLMP in the 
development of the intestine. 
In most Congenital Short Bowel Syndrome patients in whom we performed 
mutation analysis, we identified loss-of-function mutations in CLMP. However, 
we did not identify any mutation in CLMP in one family with multiple CSBS 
patients or in one isolated male CSBS patient. Because only males in the family 
were affected, an X-linked pattern of inheritance was suspected. In Chapter 4 
we describe the identification of a two-base-pair deletion in the second exon of 
FLNA in these male Congenital Short Bowel Syndrome patients. 
Altogether we identified two genes, namely CLMP and FLNA, being involved in 
Congenital Short Bowel Syndrome. That there may well be more genes involved 
in Congenital Short Bowel Syndrome is illustrated by the female patient we 
describe in Chapter 5. She had an unusual presentation of persistent pulmonary 
hypertension of the newborn and Congenital Short Bowel Syndrome. Mutation 
analysis in CLMP and FLNA did not reveal any mutations. Exome sequencing in 
this isolated female patient might reveal involvement of an additional gene in 
Congenital Short Bowel Syndrome. 
In Chapter 6 we give an overview of the literature on Congenital Short Bowel 
Syndrome. The clinical and genetic aspects are discussed as wel l  as the 
proposed hypotheses concerning the disease aetiology. We speculate on how 
the recent genetic findings help to understand the cause of Congenital Short 
Bowel Syndrome. 
The second syndrome we worked on is Megacystis-microcolon-intestinal 
hypoperistalsis syndrome (MMIHS) which is also a rare autosomal recessive 
disorder, affecting the bladder and the intestine. The genetic background of 
this disorder is unknown. However, knockout studies in mice have implicated the 
human orthologues of the a3 subunit ( CHRNA3) and the 134 subunit ( CHRNB4) 
of the nicotinic acetylcholine receptor as candidate genes. In Chapter 7 we 
describe our attempt to identify the underlying gene mutation by homozygosity 
mapping and exome sequencing in a consanguineous family with one affected 
girl .  We identified three homozygous regions on chromosomes 1, 2 and 8, 
respectively. However, no pathogenic mutation was identified in these regions. 
Neither are the candidate genes CHRNA3 and CHRNB4 located in these regions 
(making it highly unlikely that they are involved in the disease development in 
this patient). Repeating the analysis with a higher resolution array in which the 
probes are better (i.e. more evenly) distributed and with a more efficient exome 
capturing and enrichment kit, and including more patients in our study, might help 
to find the gene underlying MMIHS. 




Same nvat t i ng 
Samenvatting 
De focus van dit proefschrift is de genetische ontrafeling van het aangeboren 
korte darmsyndroom en het megacystsis-microcolon-intestinal hypoperistalsis 
syndrome. In Hoofdstuk 1 bespreken we de geschiedenis, de klinische 
presentatie, de histologische bevindingen, de genetica en de pathogenese van 
beide syndromen. 
Aangezien de syndromen voorkomen bij zowel mannen als vrouwen, de ziekten 
vrijwel altijd bij kinderen in een generatie worden gezien en niet bij de ouders, 
en omdat de ziekten vaak worden gezien bij consanguine families, wordt van 
beide syndromen gedacht dat het een autosomaal recessief overervingspatroon 
heeft. Bij consanguine families zijn de ouders familie van elkaar, zoals in nicht­
neef huwelijken. De genetische oorzaak van beide syndromen was onbekend 
toen we aan dit onderzoek begonnen. 
In Hoofdstuk 2 beschrijven wij de zoektocht naar en de ontdekking van het 
onderliggende gemuteerde gen voor het aangeboren korte darmsyndroom. 
Patienten die geboren worden met het aangeboren korte darmsyndroom hebben 
een sterk verkorte dunne darm (van gemiddeld 50 cm ten op zichte van een 
normale lengte van gemiddeld 250 cm) en een afwijkende draaiing van de 
darmen (malrotatie). Onze zoektocht begon met het zoeken naar overlappende 
homozygote gebieden bij vijf aangeboren korte darmsyndroompatienten van 
vier verschillende families. Homozygote gebieden zijn gebieden waarbij de 
DNA volgordes in een specif iek stuk van een chromosoom gelijk zijn op beide 
chromosomen, dat wil zeggen dat het stukje chromosoom dat men van zijn 
vader krijgt gelijk is aan het stukje chromosoom dat men van zijn moeder krijgt. 
Bij een autosomaal recessieve aandoening in een consanguine familie verwacht 
je namelijk dat de patient op beide chromosomen eenzelfde mutatie heeft (met 
daar omheen een gelijk stukje chromosoom), dit omdat die mutatie (en het 
stukje chromosoom rand de mutatie) afkomstig is van eenzelfde voorouder. Dus 
de patient krijgt dezelfde mutatie van die (soms verre) voorouder van zowel zijn 
moeder als van zijn vader. We hebben vijf patienten onderzocht op dergelijke 
homozygote gebieden en vonden bij vier van de vijf een overlappend homozygoot 
gebied. In dit overlappende homozygote gebied werd bij een van de patienten een 
identieke deletie op beide chromosomen (een homozygote deletie) gevonden. 
De deletie zorgt ervoor dat het tweede exon van het Coxsackie- and adenovirus 
receptor-like membrane protein (CLMP) gen afwezig is waardoor het eiwit dat 
het gen maakt niet meer goed werkt. Het screenen van de andere patienten 
voor mutaties in dit gen leidde tot de ontdekking van verschillende verlies-van­
functie mutaties in CLMP. CLMP is een celmembraaneiwit dat op dezelfde 
plaats in de eel wordt gevonden als (co-localiseert met) het tight-junction eiwit 
Z0-1. Een tight junction is het verschijnsel dat ontstaat als van twee cellen hun 
membranen samenkomen en vervolgens een soort barriere vormen ten opzichte 
van vloeibare stoffen. Verder lieten we zien dat CLMP aanwezig is in de darm van 
menselijke embryo's tijdens de gehele ontwikkeling. Het uitschakelen van het gen 
(knock-down) in zebravissen resulteerde in algemene ontwikkelingsafwijkingen, 
waaronder een verkorting van de darm en de afwezigheid van slijmbekercellen in 
de darm. Slijmbekercellen zijn karakteristiek voor de middendarm bij zebravissen. 
De middendarm komt overeen met de dunne darm bij mensen, wat suggereert 
dat de dunne darm afwezig is in deze zebravissen. 
We hebben dus verlies-van-functie mutaties gevonden in CLMP bij patienten 
met het aangeboren korte darmsyndroom. Dit suggereert een belangrijke rol 
voor CLMP in de darmontwikkeling. CLMP co-localiseert zoals gezegd met tight 
junction eiwitten, maar de functie van CLMP is niet goed bekend. In Hoofdstuk 
3 beschrijven wij proeven die we hebben gedaan om hier meer helderheid 
over te krijgen. We hebben deze 'functionele assays' gedaan in menselijke 
darmbekleding (darmepitheel) T84 cellen en in Chinese Hamster Ovarium (CHO) 
cellen. We brachten zowel normaal (wild type; WT)-CLMP als mutant-CLMP in T84 
cellen en bepaalden de rol van CLMP in migratie, celvermeerdering (proliferatie), 
levensvatbaarheid en transepitheliale electrische weerstand. Onze data lieten 
zien dat het aanwezig zijn van WT-CLMP of mutant-CLMP geen invloed heeft 
op deze processen. Daarnaast lieten onze experimenten zien dat CLMP zich 
niet gedraagt als een sterk adhesiemolecuul. Onze data suggereert dus dat, 
in het model dat wij hebben gebruikt, de sleutelprocessen die betrokken zijn 
bij darmepitheelontwikkeling niet be'invloed warden door WT-CLMP en mutant­
CLMP. Verder onderzoek is nodig om de rol van CLMP in de darmontwikkeling 
te bepalen. 
Bij de meeste patienten met het aangeboren korte darmsyndroom bij wie we op 
zoek gingen naar DNA veranderingen, vonden wij verlies-van-functie mutaties in 
CLMP. We ontdekten echter geen mutaties in CLMP in een familie met meerdere 
korte darmsyndroompatienten en in een ge"isoleerde mannelijke patient. Omdat 
in de familie alleen mannen waren aangedaan, was een X-chromosomale 
overerving waarschijnlijk. In Hoofdstuk 4 beschrijven wij de ontdekking van een 
deletie van twee basenparen in het tweede exon van FLNA in deze mannelijke 
aangeboren korte darmsyndroompatienten. 
In dit proef schrift beschrijven wij dus dat mutaties in twee genen, namelijk CLMP 
en FLNA, betrokken kunnen zijn bij het ontstaan van het aangeboren korte 
darmsyndroom. Oat er misschien meer genen betrokken zijn bij het aangeboren 
korte darmsyndroom wordt ge"illustreerd door de vrouwelijke patiente die wij 
beschrijven in Hoofdstuk 5. Ze had een ongewone presentatie van persisterende 
hoge bloeddruk in de longen (pulmonale hypertensie) en aangeboren korte 
darmsyndroom. Mutatieanalyse van CLMP en FLNA leverde geen mutaties 
op. Het sequencen van alle genen (exome sequencing) in deze ge"isoleerde 
vrouwelijke patiente zou kunnen leiden tot de ontdekking van de betrokkenheid 
van nog een gen bij het ontstaan van het aangeboren korte darmsyndroom. 
In Hoofdstuk 6 geven wij een overzicht van de literatuur over het aangeboren korte 
darmsyndroom. Zowel de klinische en genetische aspecten als de voorgestelde 
hypotheses over het ontstaan van de ziekte worden besproken. We speculeren 
over hoe de recente genetische bevindingen helpen om de oorzaak van het 
aangeboren korte darmsyndroom te begrijpen. 
Het tweede syndroom dat we hebben onderzocht is het megacysitis­
microcolon-intestinal hypoperistalsis syndrome (MMIHS). Dit syndroom is, 
net als het aangeboren korte darmsyndroom, een zeldzame autosomaal 
recessieve aandoening. Bij het megacystis-microcolon-intestinal hypoperistalsis 
syndrome zijn de blaas en de darm aangedaan. De genetische achtergrond 
van deze aandoening is onbekend. Onderzoek bij muizen waarin specifieke 
genen zijn uitgeschakeld (zogenaamde knockout muizen) leverde een aantal 
goede kandidaatgenen op, namelijk de a3 subunit (CHRNA3) en de �4 subunit 
( CHRNB4) van de nicotine acetylcholine receptor. In Hoofdstuk 7 beschrijven 
wij onze poging om de onderliggende genmutatie te vinden in een consanguine 
familie met een aangedaan meisje door opnieuw te zoeken naar homozygote 
gebieden en door alle genen in deze gebieden op mutaties te onderzoeken 
(exome sequencing). We vonden drie homozygote gebieden op respectievelijk 
chromosoom 1, 2 en 8 .  Echter, we vonden geen ziekteveroorzakende mutatie 
in deze gebieden. Ook lagen de kandidaatgenen CHRNA3 en CHRNAB niet in 
deze gebieden. Herhaling van de experimenten met betere arrays (arrays met 
meer probes en waarbij de probes meer gelijk verdeeld zijn), verbeterde exome 
sequencing (we misten met de gebruikte methode een deel van de exonen) en 
de inclusie van meer patienten in ons onderzoek, zal mogelijk helpen om het 
onderliggende gen voor MMIHS te vinden. 
In Hoofdstuk 8 bespreken wij het werk dat gepresenteerd is in dit proefschrift 
en speculeren we over de vooruitzichten voor de toekomst. 
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Li s t  o f  ab b r e v i at i o ns 
ASAM adipocyte specific adhesion molecule 
ATP2B4 plasma membrane calcium-transporting ATPase 4 
bp base pair 
CAR Coxsackie- and Adenovirus Receptor 
CDH1 cadherin 1 
cDNA complementary DNA 
CHO Chinese Hamster Ovary 
CHRNA3 neuronal nicotinic acetylcholine receptor, alpha3 subunit 
CHRNB4 neuronal nicotinic acetylcholine receptor beta 4 subunit 




























Coxsackie- and adenovirus receptor-Like Membrane Protein 
Congenital Short Bowel Syndrome 
Cortical Thymocyte marker in Xenopus 
4 ',6-diamidino-2-phenylindole 
the Single Nucleotide Polymorphism database 
Dulbecco's Modified Eagle Medium 
deoxyribonucleic acid 
GFP like protein 
Fetal Bovine Serum 
Filamin A 
glyceraldehyde-3-phosphate dehydrogenase 
Green Fluorescent Protein 
Human embryonic kidney 
interleukin 24 
internal ribosomal re-entry site 
Junctional adhesion molecules 
Madin-Darby canine kidney 
Megacystis microcolon intestinal hypoperistalsis syndrome 
messenger RNA 
Myogenin 
promoter of cytomegalovirus 
polymerase chain reaction 
quantitative polymerase chain reaction 
ribonucleic acid 
reverse-transcription polymerase chain reaction 
splice-blocking morpholino 
SNP single-nucleotide polymorphism 
TBMO translation-blocking morpholino 
TER transepithelial electrical resistance 
TPN total parenteral nutrition 
WT wild-type 
Z0-1 zonula occludens 1 
a-MEM alpha modification of eagle's medium 
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